Page last updated: 2024-09-05

sorafenib and Angiogenesis, Pathologic

sorafenib has been researched along with Angiogenesis, Pathologic in 237 studies

Research

Studies (237)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	53 (22.36)	29.6817
2010's	157 (66.24)	24.3611
2020's	27 (11.39)	2.80

Authors

Authors	Studies
Adnane, L; Auclair, D; Bollag, G; Cao, Y; Carter, C; Chen, C; Eveleigh, D; Gawlak, S; Gedrich, R; Liu, L; Lynch, M; McHugh, M; McNabola, A; Post, LE; Riedl, B; Rong, H; Rowley, B; Shujath, J; Tang, L; Taylor, I; Trail, PA; Vincent, P; Voznesensky, A; Wilhelm, SM; Wilkie, D; Zhang, X	1
Dong, J; Gao, H; Shi, Y; Su, P; Wang, C; Zhang, J; Zhang, Y	1
Bhanushali, U; Chatterjee, S; Chatti, K; Kulkarni, P; Rajendran, S; Ramaa, CS; Sarma, K	1
Li, C; Pan, X; Shan, Y; Si, R; Sun, Y; Wang, B; Zhang, J	1
Li, C; Liang, L; Pan, X; Shan, Y; Si, R; Sun, Y; Wang, B; Zhang, J	1
Bhandari, S; Bhargava, SK; Reddy, TS; Reddy, VG; Sakla, AP; Sana, S; Shankaraiah, N; Tokala, R	1
Boshagh, MA; Esmaeili, R; Faraji, A; Firoozpour, L; Foroumadi, A; Hasanvand, Z; Khalaj, A; Mehrabi, H; Motahari, R; Nazeri, E; Oghabi Bakhshaiesh, T	1
Chen, TL; Hou, MH; Jain, V; Kuppusamy, R; Lee, TC; Lin, YW; Patel, AS; Su, TL	1
Huwaimel, BI; Jonnalagadda, S; Mikelis, CM; Nocentini, A; Supuran, CT; Trippier, PC; Zahra, FT	1
Li, Q; Liu, GL; Mu, W; Zhang, JG; Zhang, X; Zhou, HM	1
Fujihara, S; Fujita, K; Goda, Y; Iwama, H; Kobara, H; Masaki, T; Morishita, A; Nakahara, M; Nishiyama, N; Shi, T; Takuma, K; Tani, J; Yamada, M; Yoneyama, H	1
Maeda, S; Momoi, Y; Yokota, S; Yonezawa, T	1
Assaraf, YG; Chen, M; Chen, ZS; Deng, L; Huang, M; Lin, Y; Wang, C; Ye, W; Zhang, D	1
Han, H; Lin, T; Liu, C; Zhai, H; Zhu, W	1
Abolmaali, SS; Azarpira, N; Borandeh, S; Dehshahri, A; Najafi, H; Rahiminezhad, Z; Tamaddon, A	1
Li, Y; Shen, J; Wu, Y; Yu, Y; Zhang, R; Zhu, J	1
Chai, MY; Chen, DX; Dou, SS; Fu, Z; Kou, BX; Liu, XN; Wei, FL	1
Górka, J; Hoffman, RM; Jura, J; Kwapisz, O; Marona, P; Miekus, K; Rys, J	1
Duda, DG; Jain, RK	1
Liu, J; Qiu, WC; Shen, XY; Sun, GC	1
Gao, G; Huang, Z; Li, L; Luo, C; Mao, Y; Qi, W; Wang, G; Yang, X; Yang, Z; Zhou, T; Zhu, L	1
Chen, ZQ; Dong, ZR; Li, T; Shi, K; Sun, D; Wang, XW; Wu, R; Yan, LJ; Yan, YC; Yang, YF; Yao, CY; Zhi, XT; Zhou, W	1
Battelli, N; Bianconi, M; Casadei Gardini, A; Cascinu, S; Demurtas, L; Falcone, A; Faloppi, L; Gadaleta, CD; Galizia, E; Giampieri, R; Lai, E; Loretelli, C; Marisi, G; Masi, G; Puzzoni, M; Scartozzi, M; Silvestris, N; Ulivi, P; Vivaldi, C; Ziranu, P	1
Gong, FL; Guo, XL; Li, YS; Wang, L; Yang, XX; Yu, LG; Zhang, XK; Zhao, L	1
Bai, YD; Feng, JQ; Li, D; Li, H; Liu, Y; Peng, JJ; Shi, ML; Sun, FF; Wang, C; Wang, D; Wang, T; Zhang, T	1
Chen, WC; Hartano, S; Ho, RZW; Huynh, H; Koh, TS; Le, TBU; Lee, P; Prawira, A; Teo, XQ; Thng, CH; Tran, A; Vu, TC	1
Chen, M; Liu, L; Ma, D; Wang, J; Wang, Z	1
Afify, SM; Atallah, MN; Hassan, G; Nawara, HM; Seno, A; Seno, M; Zahra, MH	1
Bonney, G; Chow, P; Dan, YY; Huang, DQ; Jumat, H; Kow, A; Lee, GH; Lim, SG; Lim, YT; Muthiah, MD; Pang, YH; Shridhar, I; Soon, G; Tan, WX; Wee, A; Zhou, L	1
Bhattacharya, SK; Galav, V; Gupta, R; Jain, S; Kumar, M; Meshram, GG; Prasad, A; Rastogi, T; Sharma, S	1
Chao, WT; Cheng, CC; Hsu, YH; Lai, YS; Liu, YH; Shih, JH	1
Bruchard, M; Geindreau, M; Ghiringhelli, F	1
Cai, M; Huang, W; Xing, Y; Zhu, L; Zhuo, J	1
Agarwal, N; Gill, DM; Vaishampayan, U	1
Carillio, G; Costanzo, R; Daniele, G; Manzo, A; Montanino, A; Morabito, A; Normanno, N; Perrone, F; Piccirillo, MC; Rocco, G; Sandomenico, C	1
Eguchi, R; Enomoto, H; Honda, M; Iijima, H; Imanishi, H; Iwata, Y; Kaneko, S; Nishiguchi, S; Nishikawa, H; Sato, A; Tao, L; Tsujimura, T	1
Adeniran, A; Boeke, M; Camp, RL; DiPaola, RS; Flaherty, KT; Haas, NB; Jilaveanu, LB; Kluger, HM; Manola, J; Neumeister, V; Pins, M; Puligandla, M; Wang, XV; Weiss, SA; Zito, C	1
Fu, C; Gu, H; Han, Z; Lin, J; Lu, F; Yang, S	1
Cen, J; He, Q; Hu, C; Hu, J; Hui, L; Ji, Y; Jiang, K; Kienast, Y; Li, W; Liu, X; Qiu, Z; Tian, F; Wang, Z; Zhang, H	1
Fujii, H; Hamamichi, S; Hori, Y; Ito, K; Matsui, J; Ozawa, Y; Umeda, IO	1
Benavides, R; Bishop, AJR; Chen, Y; Gonçalves, RM; Gorthi, A; Kuhn, J; Loranc, E; Masamsetti, VP; Rajamanickam, S; Reddick, RL; Romero, JC; Tonapi, S; Zanotto-Filho, A	1
Cao, YW; Dong, Z; Guo, L; Kang, EH; Liu, Y; Niu, HT; Wang, YH; Zhang, W	1
Aprile, G; Brunetti, O; Bruno, D; Calvetti, L; Caparello, C; Cascinu, S; Chessa, L; Corbelli, J; Dadduzio, V; Ercolani, G; Faloppi, L; Farella, N; Foschi, FG; Frassineti, GL; Gardini, AC; Gentilucci, UV; Lanzi, A; Leonetti, A; Marisi, G; Masi, G; Negri, FV; Pagan, F; Santini, D; Scarpi, E; Scartozzi, M; Silletta, M; Silvestris, N; Stefano, G; Tamburini, E; Tassinari, D; Vivaldi, C; Zagonel, V	1
Huang, K; Liu, CH; Liu, HL; Lü, J; Sun, X; Tao, YY; Zhao, ZM	1
Chai, CY; Chiang, CM; Chiou, SS; Hsu, SH; Huang, SK; Liu, KY; Wang, LT; Wang, SN; Yokoyama, KK	1
Abada, PB; Finn, RS; He, AR; Kim, R; Morse, MA; Mynderse, M; Sun, W	1
Chen, X; Ma, S; Mei, Q; Wang, J; Wang, Z; Zhang, S	1
Avritscher, R; Bankson, JA; Cortes, AC; Ensor, JE; Kingsley, CV; Maldonado, KL; Minhaj, AA; Mitchell, JM; Muñoz, NM; Polak, U; Rashid, A; Taghavi, H	1
Al-Naamani, N; Brown, R; Doyle, MF; Ellenberg, SS; Fallon, MB; Fox, A; Goldberg, D; Gupta, S; Kaplan, DE; Kawut, SM; Koch, D; Krowka, MJ; Levitsky, J; Lin, G; Mottram, C; Oh, JK; Sharkoski, T; Song, N; Vargas, H	1
Arai, S; Fukuda, K; Hirata, E; Matsui, J; Nishiyama, A; Ohtsubo, K; Onoda, N; Taira, S; Takeuchi, S; Taniguchi, H; Tanimoto, A; Wang, R; Yamada, T; Yamashita, K; Yano, S	1
Du, Y; Liang, Q; Liu, S; Ma, H; Tian, J; Zhu, X	1
Personeni, N; Pressiani, T; Rimassa, L	1
Badarau, IA; Caruntu, C; Constantin, C; Didilescu, AC; Mihai, GL; Neagu, M; Scheau, C	1
Barzakova, E; Bruners, P; Isfort, P; Kuhl, CK; Pedersoli, F; Schulze-Hagen, M; Thüring, J; Zimmermann, M	1
Dai, Z; Fan, J; Gu, F; Huang, X; Jiang, J; Tan, C; Wang, Z; Xu, M; Yan, J; Zhou, J	1
Aglietta, M; Alberghini, M; Basiricò, M; Bruno, S; Capozzi, F; D'Ambrosio, L; Dell'Aglio, C; Fagioli, F; Ferrari, S; Gammaitoni, L; Grignani, G; Marchiò, S; Picci, P; Pignochino, Y; Sangiolo, D; Soster, M; Torchiaro, E	1
Annunziata, CM; Azad, N; Calvo, K; Chen, CC; Choyke, P; Davidson, B; Edelman, DC; Henning, R; Kohn, EC; Meltzer, P; Minasian, L; Steinberg, SM; Venkatesan, A; Wood, BJ; Yu, M	1
O'Neil, B; Sampat, KR	1
Bargellini, I; Bartolozzi, C; Battaglia, V; Bertini, M; Bresci, G; Faggioni, L; Ginanni, B; Romano, A; Sacco, R	1
Chong, DQ; Choo, SP; Tan, IB; Toh, HC	1
Carlo-Stella, C; Cleris, L; Giacomini, A; Gianni, AM; Guidetti, A; Locatelli, SL; Righi, M; Saba, E	1
Waxman, DJ; Zhang, K	1
Chai, ZT; Gao, DM; Kong, LQ; Lu, L; Sun, HC; Tang, ZY; Wang, L; Wang, WQ; Wu, WZ; Xu, HX; Zhang, JB; Zhang, W; Zhu, XD; Zhuang, PY	1
Aziz, K; Cades, JA; Chettiar, ST; Cosgrove, D; Gajula, RP; Gandhi, N; Geschwind, JF; Hales, RK; Herman, JM; Kumar, R; Maitra, A; Menon, S; Pawlik, TM; Taparra, K; Torbenson, MS; Tran, PT; Velarde, E; Wild, AT; Williams, RD; Wong, J; Zeng, J	1
Dokduang, H; Juntana, S; Khuntikeo, N; Loilome, W; Namwat, N; Riggins, GJ; Techasen, A; Yongvanit, P	1
Bartsch, DK; Doll, D; Greene, BH; Hoffmann, S; Khoruzhyk, M; Ramaswamy, A; Roth, S; Wunderlich, A	1
Benedetto, C; Bussolati, B; Moggio, A; Pittatore, G; Revelli, A	1
Hagihara, H; Honda, M; Ikeda, F; Iwadou, S; Kaneko, S; Kariyama, K; Kobayashi, Y; Kuwaki, K; Miyahara, K; Miyake, Y; Morimoto, Y; Nakamura, S; Nouso, K; Obi, S; Onishi, H; Sato, S; Sato, T; Shiraha, H; Takabatake, H; Takaguchi, K; Takaki, A; Takeuchi, Y; Takuma, Y; Yamamoto, K	1
Aihara, Y; Douhara, A; Fukui, H; Kawaratani, H; Kitade, M; Moriya, K; Namisaki, T; Nishimura, N; Noguchi, R; Yoshiji, H	1
Alpini, G; Fallon, MB; Hu, B; Venter, J; Wu, W; Yang, W; Zhang, J	1
Li, W; Lu, Y; Qin, Y; Qu, X; Wang, R	1
Fukatsu, A; Gotoh, M; Hattori, R; Kuroda, M; Kuwahara, K; Morikawa, T; Sassa, N; Shimoyama, Y; Shiroki, R; Tsuzuki, T; Yoshino, Y	1
Saif, MW	1
Abd-Alhaseeb, MM; Abou-El-Ela, SH; Moustafa, YM; Zaitone, SA	1
Li, Y; Meng, Q; Shen, J; Sun, H; Yin, Q; Yu, H; Zhang, Z	1
Bearzi, I; Benedetti, A; Bianconi, M; Bitetto, D; Bolondi, L; Cascinu, S; Colombo, M; D'Errico, A; De Minicis, S; Facchetti, F; Faloppi, L; Fava, G; Gemini, S; Giampieri, R; Granito, A; Iavarone, M; Loretelli, C; Mandolesi, A; Marinelli, S; Piscaglia, F; Scartozzi, M; Svegliati Baroni, G; Toniutto, P; Vavassori, S; Venerandi, L	1
Colecchia, M; De Braud, F; Garanzini, E; Grassi, P; Iacovelli, R; Procopio, G; Testa, I; Torelli, T; Verzoni, E	1
Deng, DF; Ding, LM; Kang, XS; Qiu, YQ; Tan, FL; Yu, W; Zhou, J	1
Ambrosetti, D; Amiel, J; Gastaud, L; Grépin, R; Marsaud, A; Pagès, G; Pedeutour, F	1
Chen, LJ; Chen, YZ; Cheng, C; Fu, XY; Li, LL; Tang, Y; Wei, YQ; Xiang, R; Yang, J; Yang, LL; Yang, SY; Zhong, L; Zhou, S; Zou, C	1
Ito, K; Sugino, K; Takami, H	1
Baron Toaldo, M; Bolondi, L; Croci, L; Diana, A; Marinelli, S; Milazzo, M; Palamà, C; Pecorelli, A; Piscaglia, F; Salvatore, V; Venerandi, L	1
Bogaerts, E; Colle, I; Descamps, B; Devisscher, L; Geerts, A; Janssens, S; Lambrecht, BN; Laukens, D; Libbrecht, L; Paridaens, A; Van Steenkiste, C; Van Vlierberghe, H; Vandewynckel, YP; Vanhove, C; Verhelst, X	1
Liu, C; Liu, L; Long, J; Ni, QX; Sun, HC; Tang, ZY; Wang, WQ; Wu, CT; Xu, HX; Xu, J; Yu, XJ; Zhang, W; Zhu, XD	1
Anouar, Y; Baudin, E; Denorme, M; Dubessy, C; Gonzalez, BJ; Roux, C; Yon, L	1
Blacher, S; Calligaris, D; Cimino, J; De Pauw, E; De Tullio, P; Debois, D; Mari, B; Mazzucchelli, G; Noel, A; Paye, A; Primac, I; Sounni, NE; Truong, A	1
Baron Toaldo, M; Bolondi, L; Cipone, M; Croci, L; Marinelli, S; Milazzo, M; Palamà, C; Piscaglia, F; Salvatore, V; Venerandi, L	1
Dong, X; Jiang, X; Li, G; Li, J; Ma, L; Ni, S; Qiao, H; Sun, X; Zhao, D; Zhu, H	1
Jung, WG; Kim, EH; Kim, MS	1
Armeanu-Ebinger, S; Dewerth, A; Fuchs, J; Nagel, C; Warmann, SW	1
Du, G; Tian, J; Wang, H; Ye, L; Yu, P; Zhang, J; Zuo, Y	1
Cao, H; Chen, L; Chen, Y; Gu, W; He, X; Huang, Y; Li, Y; Wang, Y; Xu, M; Yin, Q; Yu, H; Zhang, Z	1
De Velasco, MA; Hatanaka, Y; Kura, Y; Minami, T; Nishio, K; Nozawa, M; Oki, T; Ozeki, T; Shimizu, N; Uemura, H; Yamamoto, Y; Yoshikawa, K; Yoshimura, K	1
Altomonte, J; Braren, R; Dworniczak, J; Ebert, O; Esposito, I; Feuchtinger, A; Groß, C; Heid, I; Heß, J; Rummeny, E; Sayyed, S; Schlitter, AM; Schwaiger, M; Settles, M; Steiger, K; Steingötter, A; Unger, K; Walch, A; Zitzelsberger, H	1
Cho, KJ; Han, KH; Kim, da Y; Kim, DY; Kim, MN; Lim, HY; Park, JH; Ro, SW	1
Brown, JM; Chang, DT; Deng, L; Giaccia, A; Koong, AC; Le, QT; Loo, BW; Pai, RK; Pollom, EL; Shultz, DB	1
Guo, XL; Li, WB; Lu, YY; Wang, JJ; Zhang, XK	1
Trojan, J; Waidmann, O	1
Batteux, F; Cerles, O; Chapron, C; Chouzenoux, S; Dousset, B; Leconte, M; Marcellin, L; Santulli, P	1
Chen, Y; Chern, GG; Chiang, T; Gao, DY; Lin, TT; Liu, CH; Liu, JY	1
Djokovic, D; Duarte, A; Gigante, J; Harris, AL; Pinho, M; Trindade, A	1
Devapatla, B; Sharma, A; Woo, S	1
Crawford, K; Dusing, M; Frischer, JS; Knod, JL	1
Ni, Y; Tian, J; Wang, H; Wang, W; Yao, Z; Ye, L	1
Meng, Z; Ning, Z; Wang, H; Xu, L; Zhang, C; Zhu, X	1
Kapiteijn, E; Morreau, H; Schneider, TC; Smit, JWA; van der Hoeven, JJM; van Wezel, T	1
Alexandre, J; Arrondeau, J; Blanchet, B; Boudou-Rouquette, P; Bretagne, M; Cabanes, L; Cessot, A; Chahwakilian, A; Coriat, R; Goldwasser, F; Huillard, O; Orvoen, G; Thomas-Schoemann, A; Tlemsani, C	1
Ellis, LM; Harris, AL; Jayson, GC; Kerbel, R	1
Bar-Zion, A; Butz, H; Daley, F; Foster, FS; Kerbel, RS; Kuczynski, EA; Lee, CR; Man, S; Reynolds, AR; Vermeulen, PB; Yin, M; Yousef, GM	1
Amadoz, A; Carbonell-Caballero, J; Crespo, D; Çubuk, C; Dopazo, J; Hidago, MR; Medina, I; Salavert, F	1
Andreoli, JM; Baker, T; Gabr, A; Hickey, R; Kallini, JR; Kircher, S; Kulik, L; Lewandowski, RJ; Salem, R	1
Fu, CX; Gao, DM; Han, ZH; Lin, J; Liu, H; Lu, F; Lv, P; Yang, SH	1
Cai, H; Kong, WT; Tang, Y; Wang, WP; Zhang, XL	1
Alsinet, C; Dauch, D; Esteller, M; Llovet, JM; Lujambio, A; Martinez-Quetglas, I; Moeini, A; Pinyol, R; Portela, A; Rodriguez-Carunchio, L; Solé, M; Thung, S; Torrecilla, S; Tovar, V; Villanueva, A; Zender, L	1
Heo, J; Woo, HY; Yoo, SY	1
Kerbel, RS; Kuczynski, EA	1
Gallacher, D; Gallacher, J; Jones, A; Narov, K; Sampson, JR; Samsel, PA; Shen, MH; Yang, J	1
Aihara, A; Akiyama, Y; Arii, S; Ban, D; Kudo, A; Matsumura, S; Mitsunori, Y; Mogushi, K; Nakao, K; Ochiai, T; Ohata, Y; Shimada, S; Tanabe, M; Tanaka, S	1
Kester, M; Robertson, GP; Smith, CD; Tran, MA	1
Blumenschein, G	1
Del Conte, G; Guibal, A; Rüegg, C; Sessa, C	1
Fan, J; Huang, XW; Qiu, SJ; Tang, ZY; Wang, Z; Yu, Y; Zhou, J	1
Chan, P; Epstein, R; Poon, RT; Yau, T	1
Greten, TF; Malek, N; Manns, MP	1
Boucher, E; Bruix, J; Forner, A; Reig, M	1
Lee, WM; Tsai, JH	1
Oseini, AM; Roberts, LR	1
Elfiky, AA; Rosenberg, JE	1
Aburatani, H; Hirakawa, K; Iwata, C; Johansson, E; Kano, MR; Kiyono, K; Komuro, A; Matsumoto, Y; Miyazono, K; Miyoshi, H; Morishita, Y; Shirai, YT; Suzuki, HI; Watanabe, A; Yashiro, M	1
Armand, JP; Domont, J; Lassau, N; Le Cesne, A; Massard, C; Soria, JC	1
Maitland, ML; Snider, KL	1
Billemont, B; Kelly, RJ; Rixe, O	1
Alsop, DC; Atkins, MB; Goldberg, SN; Lenkinski, RE; Marquis, RP; Pedrosa, I; Regan, M; Schor-Bardach, R; Signoretti, S; Solazzo, SA; Wang, X	1
Shibuya, M	1
Cortés-Funes, H	1
Dai, Z; Fan, J; Yu, L; Zhou, J	1
Dudley, AC; Klagsbrun, M	1
Qin, LX; Sun, HC; Tang, ZY; Wang, L; Wu, WZ; Xiong, YQ; Zhang, JB; Zhang, W; Zhu, XD; Zhuang, PY	1
Carlo-Stella, C; Giacomini, A; Gianni, AM; Lavazza, C; Righi, M; Sia, D	1
Angermayr, B; Gangl, A; Mitterhauser, M; Peck-Radosavljevic, M; Reiberger, T; Rohr-Udilova, N; Schwabl, P	1
Song, IH	1
Garnock-Jones, KP; Keating, GM	1
Choo, SP; Chow, P; Chung, A; Goh, BC; Huynh, H; Koong, HN; Ngo, VC; Ong, HS; Poon, D; Smith, PD; Soo, KC; Thng, CH; Toh, HC	1
Cabrera, R; Nelson, DR	1
Aglietta, M; Alberghini, M; Bottos, A; Bruno, S; Bussolino, F; Camussi, G; Cavalloni, G; Fagioli, F; Ferrari, S; Gammaitoni, L; Grignani, G; Migliardi, G; Motta, M; Picci, P; Pignochino, Y; Tapparo, M; Torchio, B	1
Bitzer, M; Claussen, CD; Hartmann, JT; Horger, M; Maksimovic, O; Pintoffl, J; Schraml, C	1
Alfano, RW; Bugge, TH; Duesbery, NS; Frankel, AE; Lairmore, TC; Leppla, SH; Liu, S; Mitchell, IC; Nwariaku, F; Ortiz, JM	1
Peter, S; Rohde, D; Tong, TQ	1
Kerbel, RS; Lee, CR; Man, S; Tang, TC; Xu, P	1
Ayllon, J; Barrascout, E; Cuenod, CA; Elaidi, R; Medioni, J; Mejean, A; Oudard, S; Scotte, F; Tartour, E	1
Altieri, DC; Gilbert, CA; Raskett, CM; Ross, AH; Siegelin, MD	1
Deville, JL; Duffaud, F; Huynh, T; Salas, S	1
Baumann, B; Büchler, MW; Gladkich, J; Herr, I; Kallifatidis, G; Liu, L; Mattern, J; Rausch, V; Salnikov, AV; Schemmer, P; Wirth, T; Zöller, M	1
Cheng, AL; Hsu, C; Shen, YC	1
Bono, AV; Cheng, L; Cunico, SC; Iezzi, M; Liberatore, M; Montironi, R; Musiani, P; Pannellini, T; Sasso, F	1
Castelo, B; Espinosa, E; Pinto, A; Redondo, A; Zamora, P	1
Cawkwell, L; Little, SJ; Maraveyas, A; Murray, A; Stanley, P	1
Barbier, EL; Bouchet, A; Coquery, N; Le Duc, G; Lemasson, B; Maisin, C; Rémy, C; Robert, P; Serduc, R; Troprès, I	1
Bawa, O; Benatsou, B; Koscielny, S; Lassau, N; Leguerney, I; Massard, C; Opolon, P; Peronneau, P; Roche, A; Rodrigues, M; Rouffiac, V; Thalmensi, J	1
Andersen, JL; Andersson, M; Kamby, C; Nielsen, DL	1
Boulton, ME; Cai, J; Han, S; Law, B; Liao, D; Qing, R	1
Carroll, AR; Coleman, RL; Sood, AK	1
Cao, L; Choyke, P; Force, J; Giaccone, G; Gutierrez, M; Keen, C; Kelly, RJ; Kummar, S; Lopez-Chavez, A; Raffeld, M; Rajan, A; Steinberg, SM; Turkbey, B; Wright, JJ; Xi, L; Yu, Y	1
Chen, BB; Cheng, AL; Hsu, C; Hsu, CH; Hsu, CY; Hu, FC; Shen, YC; Shih, TT; Wei, SY; Yu, CW	1
Cheng, CW; Chong, TW; Huynh, H; Lau, WK; Sim, MY; Siml, HG; Yuen, JS	1
Maráz, A	1
Afthinos, M; Djonov, V; Dufour, JF; Hlushchuk, R; McSheehy, PM; Piguet, AC; Radojevic, V; Saar, B; St-Pierre, MV; Terracciano, L	1
Danesi, R; Del Tacca, M; Mey, V; Pasqualetti, G; Ricciardi, S	1
Kumar, B; Kumar, P; Teknos, TN; Yadav, A	1
Cunningham, D; Okines, AF; Reynolds, AR	1
Dai, Z; Fan, J; Hu, J; Huang, XW; Qiu, SJ; Tan, CJ; Wang, Z; Zhou, J	1
Bareford, MD; Burow, ME; Cruickshanks, N; Dent, P; Fisher, PB; Grant, S; Hamed, HA; Moran, RG; Nephew, KP; Tang, Y	1
Choo, SP; Chow, PK; Chung, AY; Huynh, H; Ong, R; Soo, KC; Tai, WM; Toh, HC	1
Liu, Q; Mier, JW; Panka, DJ	1
Anderson, KC; Podar, K	1
Galle, PR; Gamstätter, T; Niederle, IM; Schadmand-Fischer, S; Schuchmann, M; Spies, PR; Weinmann, A; Wörns, MA	1
Fiedler, W; Wellbrock, J	1
Reed, MW; Young, RJ	1
Chlenski, A; Cohn, SL; Guerrero, LJ; Kakodkar, NC; Maitland, ML; Peddinti, RR; Salwen, HR; Tian, Y; Yang, Q	1
Armeanu-Ebinger, S; Dewerth, A; Eicher, C; Fuchs, J; Kirchner, B; Warmann, SW	1
Fukumoto, M; Matsuda, Y	1
Allavena, P; Mantovani, A	1
Boulanger, G; Edeline, J; Jouan, F; Martin, B; Oger, E; Patard, JJ; Rioux-Leclercq, N; Vigneau, C; Zerrouki, S	1
Döme, B; Török, S	1
Spechler, SJ; Wang, DH; Xie, B	1
Dong, Z; Nör, JE; Zeitlin, BD	1
Chung, AS; Ferrara, N; Finkle, D; Komuves, L; Kowanetz, M; Ngu, H; Peale, F; Wu, X; Zhuang, G	1
Dauser, B; Dienes, HP; Dufour, JF; Hayden, H; Peck-Radosavljevic, M; Piguet, AC; Pinter, M; Prager, G; Rohr-Udilova, N; Sieghart, W	1
Spârchez, Z	1
Chatzimichail, K; Gkoutzios, P; Kalokairinou, M; Karagiannis, E; Kiltenis, M; Kornezos, I; Malagari, K; Moschouris, H; Papadaki, MG; Stamatiou, K	1
Gold, KA; Kim, E; Zhang, J	1
Gao, H; Hu, S; Jiang, H; Kong, J; Li, Z; Shi, B; Yang, Y; Yao, M; Zhang, P	1
Azzolina, A; Bachvarov, D; Cervello, M; Cusimano, A; Lampiasi, N; McCubrey, JA; Montalto, G	1
Kaklamani, V; Raffin, M; Reddy, S	1
Amigo, G; Antón, A; Esquerdo, G; García-Otín, AL; Lanzuela, M; Martín-Duque, P; Pazo-Cid, RA; Pérez-Gracia, JL; Trufero, JM	1
Matsui, O	1
Fan, X; Haney, CR; Karczmar, GS; Markiewicz, E; Mustafi, D; Stadler, WM	1
Chen, GG; Ho, RL; Lai, PB; Liu, LP	1
Abou-Alfa, GK; Ang, C; O'Reilly, EM	1
Bussolati, B; Cassoni, P; Marchino, GL; Moggio, A; Pittatore, G; Revelli, A	1
Allemeersch, J; Carmeliet, P; Casteleyn, C; Colle, I; Coulon, S; Geerts, A; Heindryckx, F; Libbrecht, L; Stassen, JM; Terrie, E; Van Vlierberghe, H	1
Huang, GL; Liu, GJ; Lü, MD; Wang, W; Xie, XH; Xie, XY; Xu, M; Xu, ZF; Zheng, SG; Zheng, YL	1
Chen, J; Sun, W; Xu, WF; Yao, JW	1
Armeanu-Ebinger, S; Dewerth, A; Eicher, C; Ellerkamp, V; Fuchs, J; Hildenbrand, S; Thomale, J; Warmann, SW	1
Han, KH; Kim, DY	1
Brandt, R; Dredge, K; Hammond, E	1
Bartsch, DK; Buchholz, M; Fendrich, V; Holler, JP; Maschuw, K; Rehm, J; Slater, EP; Waldmann, J	1
Ashida, S; Fukuhara, H; Inoue, K; Kamada, M; Karashima, T; Kuroda, N; Shuin, T; Taguchi, T; Tamura, K	1
Robertson, GP; Sharma, A; Smith, CD; Trivedi, NR; Tuveson, DA; Zimmerman, MA	1
Hedley, D; Siu, LL; Sridhar, SS	1
Herbst, RS; Onn, A; Sandler, A	1
Schiller, JH; Wakelee, HA	1
Soff, G; Zakarija, A	1
Rini, BI	3
Carter, C; Feldman, MD; Lassoued, W; Lee, WM; Makonnen, S; Murphy, DA	1
Cao, Y; Carter, C; Chen, C; Liu, L; Lynch, M; McNabola, A; Wilhelm, S; Wilkie, D; Zhang, X	1
Schneider, BP; Sledge, GW	1
McKeage, K; Wagstaff, AJ	1
Miroglu, C; Silay, MS	1
Angele, MK; Bruns, CJ; Eichhorn, ME; Jauch, KW; Kleespies, A	1
Baz, RC; Bukowski, RM; Choueiri, TK; Elson, P; Garcia, JA; Golshayan, AR; Khasawneh, M; Rini, BI; Usman, S; Wood, L	1
Cabebe, E; Wakelee, H	1
Blansfield, JA; Kachala, S; Libutti, SK; Lorang, D; Mangiameli, DP; Muller, GW; Schafer, PH; Stirling, DI	1
Atkins, MB; Goldberg, SN; Hakimé, A; Hines-Peralta, A; Peddi, H; Regan, M; Signoretti, S; Sukhatme, VP	1
Bodrogi, I	1
Armand, JP; Mir, O; Ropert, S	1
Billemont, B; Izzedine, H; Méric, JB; Rixe, O; Sultan-Amar, V; Taillade, L	1
Alba, E; Medina, MA; Quesada, AR	1
Culine, S; Pouessel, D	1
Culine, S; Patard, JJ; Pouessel, D; Verhoest, G	1
Chi, KN; Czaykowski, P; Ellard, SL; Gauthier, I; Hansen, C; Hotte, SJ; Moore, M; Ruether, JD; Schell, AJ; Seymour, L; Taylor, S; Walsh, W	1
Flaherty, KT; Gallagher, ML; Heitjan, DF; O'Dwyer, PJ; Rosen, MA; Schnall, MD; Schwartz, B	1
Giordano, S; Petrelli, A	1
Lee, CB; Socinski, MA	1

Reviews

70 review(s) available for sorafenib and Angiogenesis, Pathologic

Article	Year
New insights into antiangiogenic therapy resistance in cancer: Mechanisms and therapeutic aspects. Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy, 2022, Volume: 64 Topics: Angiogenesis Inhibitors; Animals; Bevacizumab; Endothelial Cells; Granulocyte Colony-Stimulating Factor; Granulocyte-Macrophage Colony-Stimulating Factor; Mice; Neoplasms; Neovascularization, Pathologic; Sorafenib	2022
Vascular Endothelial Growth Factor, a Key Modulator of the Anti-Tumor Immune Response. International journal of molecular sciences, 2021, May-04, Volume: 22, Issue:9 Topics: Adaptive Immunity; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Capillary Permeability; Endothelial Cells; Gene Expression Regulation, Neoplastic; Humans; Immunity, Innate; Immunologic Factors; Neoplasms; Neovascularization, Pathologic; Ramucirumab; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Signal Transduction; Sorafenib; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-1	2021
Evolving Treatment Paradigm in Metastatic Renal Cell Carcinoma. American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting, 2017, Volume: 37 Topics: Carcinoma, Renal Cell; Cell Proliferation; Gene Expression Regulation, Neoplastic; Humans; Indoles; Neoplasm Metastasis; Neoplasm Proteins; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrroles; Quinolines; Sorafenib; Sunitinib; Von Hippel-Lindau Tumor Suppressor Protein	2017
Angiogenesis Inhibitors in NSCLC. International journal of molecular sciences, 2017, Sep-21, Volume: 18, Issue:10 Topics: Adenocarcinoma; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Disease-Free Survival; Docetaxel; Humans; Indoles; Lung Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Piperidines; Pyrroles; Quinazolines; Ramucirumab; Sorafenib; Sunitinib; Taxoids	2017
The Role of Angiogenesis in Hepatocellular Carcinoma. Clinical cancer research : an official journal of the American Association for Cancer Research, 2019, 02-01, Volume: 25, Issue:3 Topics: Angiogenesis Inhibitors; Angiostatins; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Neovascularization, Pathologic; Prognosis; Protein Kinase Inhibitors; Sorafenib; Vascular Endothelial Growth Factor A	2019
Cabozantinib in patients with hepatocellular carcinoma failing previous treatment with sorafenib. Future oncology (London, England), 2019, Volume: 15, Issue:21 Topics: Anilides; Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Clinical Trials as Topic; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Humans; Liver Neoplasms; Molecular Structure; Molecular Targeted Therapy; Neoplasm Staging; Neovascularization, Pathologic; Prognosis; Protein Kinase Inhibitors; Pyridines; Randomized Controlled Trials as Topic; Retreatment; Sorafenib; Treatment Outcome	2019
Capsaicin: Effects on the Pathogenesis of Hepatocellular Carcinoma. Molecules (Basel, Switzerland), 2019, Jun-26, Volume: 24, Issue:13 Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Capsaicin; Carcinoma, Hepatocellular; Cell Differentiation; Cell Proliferation; Drug Synergism; Humans; Liver Neoplasms; Neovascularization, Pathologic; Oxidative Stress; Signal Transduction; Sorafenib; TRPV Cation Channels	2019
Antiangiogenic therapies for advanced hepatocellular carcinoma. The oncologist, 2013, Volume: 18, Issue:4 Topics: Angiogenesis Inhibitors; Carcinoma, Hepatocellular; Fibroblast Growth Factors; Humans; Liver Neoplasms; Molecular Targeted Therapy; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Platelet-Derived Growth Factor; Sorafenib; Vascular Endothelial Growth Factor A	2013
Endometrial adult/progenitor stem cells: pathogenetic theory and new antiangiogenic approach for endometriosis therapy. Reproductive sciences (Thousand Oaks, Calif.), 2014, Volume: 21, Issue:3 Topics: Adult; Adult Stem Cells; Angiogenesis Inhibitors; Animals; Endometriosis; Endometrium; Female; Humans; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Sorafenib	2014
Development of molecular targeted drugs for advanced thyroid cancer in Japan. Endocrine journal, 2014, Volume: 61, Issue:9 Topics: Antineoplastic Agents; Clinical Trials as Topic; Humans; Japan; Molecular Targeted Therapy; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Piperidines; Quinazolines; Quinolines; Sorafenib; Thyroid Neoplasms	2014
Gastrointestinal Toxicities With Combined Antiangiogenic and Stereotactic Body Radiation Therapy. International journal of radiation oncology, biology, physics, 2015, Jul-01, Volume: 92, Issue:3 Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Combined Modality Therapy; Gastrointestinal Tract; Humans; Intestine, Small; Neoplasms; Neovascularization, Pathologic; Niacinamide; Organs at Risk; Phenylurea Compounds; Radiosurgery; Sorafenib; Time Factors; Vascular Endothelial Growth Factor A	2015
Novel drugs in clinical development for hepatocellular carcinoma. Expert opinion on investigational drugs, 2015, Volume: 24, Issue:8 Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Hepatocellular; Drug Design; Humans; Liver Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Sorafenib	2015
[Tyrosine kinase inhibiting the VEGF pathway and elderly people: Tolerance, pre-treatment assessment and side effects management]. Bulletin du cancer, 2016, Volume: 103, Issue:3 Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Axitinib; Fatigue; Humans; Imidazoles; Indazoles; Indoles; Kidney; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Pyridines; Pyrroles; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sunitinib	2016
Antiangiogenic therapy in oncology: current status and future directions. Lancet (London, England), 2016, Jul-30, Volume: 388, Issue:10043 Topics: Angiogenesis Inhibitors; Angiopoietin-1; Biomarkers, Tumor; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Molecular Targeted Therapy; Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Protein Kinase Inhibitors; Quinazolines; Quinolines; Receptor, TIE-2; Signal Transduction; Sorafenib; Vascular Endothelial Growth Factor A	2016
New chemical treatment options in second-line hepatocellular carcinoma: what to do when sorafenib fails? Expert opinion on pharmacotherapy, 2017, Volume: 18, Issue:1 Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-met; Sorafenib	2017
Sorafenib in lung cancer: clinical developments and future directions. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2008, Volume: 3, Issue:6 Suppl 2 Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Non-Small-Cell Lung; Female; Follow-Up Studies; Forecasting; Humans; Lung Neoplasms; Male; Neoplasm Staging; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Pyridines; Randomized Controlled Trials as Topic; Receptors, Vascular Endothelial Growth Factor; Risk Assessment; Sorafenib; Survival Analysis; Treatment Outcome; Vascular Endothelial Growth Factors	2008
Biomarkers of angiogenesis for the development of antiangiogenic therapies in oncology: tools or decorations? Nature clinical practice. Oncology, 2008, Volume: 5, Issue:7 Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Biomarkers, Tumor; Clinical Trials as Topic; Humans; Indoles; Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sorafenib; Sunitinib	2008
Management of advanced hepatocellular carcinoma in the era of targeted therapy. Liver international : official journal of the International Association for the Study of the Liver, 2009, Volume: 29, Issue:1 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Carcinoma, Hepatocellular; Drug Delivery Systems; Epidermal Growth Factor; Humans; Mitogen-Activated Protein Kinases; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Phosphatidylinositol 3-Kinases; Pyridines; Signal Transduction; Sorafenib	2009
[Sorafenib for the treatment of HCC--the beginning of a new era in the treatment of HCC]. Zeitschrift fur Gastroenterologie, 2009, Volume: 47, Issue:1 Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Controlled Clinical Trials as Topic; Drug Delivery Systems; Humans; Liver Neoplasms; Neoplasm Staging; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib	2009
New drugs for the treatment of hepatocellular carcinoma. Liver international : official journal of the International Association for the Study of the Liver, 2009, Volume: 29 Suppl 1 Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Drug Delivery Systems; ErbB Receptors; Humans; Mitogen-Activated Protein Kinase 1; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Pyridines; Receptors, Growth Factor; Signal Transduction; Sorafenib	2009
PDGFRalpha: a new therapeutic target in the treatment of hepatocellular carcinoma? Expert opinion on therapeutic targets, 2009, Volume: 13, Issue:4 Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Clinical Trials as Topic; Drug Delivery Systems; Drug Design; Embryonic Development; Humans; Liver Neoplasms; Liver Neoplasms, Experimental; Mice; Mice, Transgenic; Neoplasm Proteins; Neovascularization, Pathologic; Neovascularization, Physiologic; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Receptor, Platelet-Derived Growth Factor alpha; Signal Transduction; Sorafenib	2009
Targeting angiogenesis in bladder cancer. Current oncology reports, 2009, Volume: 11, Issue:3 Topics: Angiogenesis Inhibitors; Antibodies; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Humans; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Pyridines; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Urinary Bladder Neoplasms; Vascular Endothelial Growth Factor A	2009
Cardiovascular toxicities: clues to optimal administration of vascular endothelial growth factor signaling pathway inhibitors. Targeted oncology, 2009, Volume: 4, Issue:2 Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Drug Administration Routes; Female; Hemorrhage; Humans; Hypertension; Indoles; Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Pyrroles; Signal Transduction; Sorafenib; Sunitinib; Treatment Outcome; Vascular Endothelial Growth Factor A	2009
Renal toxicity of targeted therapies. Targeted oncology, 2009, Volume: 4, Issue:2 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Clinical Trials as Topic; Drug Evaluation, Preclinical; Humans; Hypertension; Indoles; Kidney; Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Proteinuria; Pyridines; Pyrroles; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A	2009
Angiogenesis regulated by VEGF and its receptors and its clinical application. [Rinsho ketsueki] The Japanese journal of clinical hematology, 2009, Volume: 50, Issue:5 Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Drug Design; Humans; Indoles; Neoplasms; Neoplastic Cells, Circulating; Neovascularization, Pathologic; Neovascularization, Physiologic; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Signal Transduction; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A	2009
The role of antiangiogenesis therapy: bevacizumab and beyond. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2009, Volume: 11, Issue:6 Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Clinical Trials as Topic; Combined Modality Therapy; Drug Delivery Systems; Forecasting; Humans; Indoles; Neoadjuvant Therapy; Neoplasm Proteins; Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sirolimus; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A	2009
[Current advances in molecular targeted therapy of primary hepatocellular carcinoma]. Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2009, Volume: 17, Issue:6 Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Cell Adhesion; Cell Proliferation; Humans; Liver Neoplasms; Neoplasm Metastasis; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Pyridines; Signal Transduction; Sorafenib	2009
Molecular targeting for treatment of advanced hepatocellular carcinoma. The Korean journal of hepatology, 2009, Volume: 15, Issue:3 Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-raf; Pyridines; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Sorafenib	2009
Review article: the management of hepatocellular carcinoma. Alimentary pharmacology & therapeutics, 2010, Feb-15, Volume: 31, Issue:4 Topics: Ablation Techniques; Adult; Antineoplastic Agents; Asian People; Benzenesulfonates; Biopsy; Black People; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Contrast Media; Drug Eruptions; Female; Health Care Costs; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Incidence; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Neoplasm Staging; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Population Surveillance; Practice Guidelines as Topic; Pyridines; Quality of Life; Randomized Controlled Trials as Topic; Recurrence; Risk Factors; Sorafenib; Survival Rate; Tomography, X-Ray Computed; Treatment Outcome; United States; Young Adult	2010
Progress in the management of advanced renal cell carcinoma (RCC). Aktuelle Urologie, 2010, Volume: 41 Suppl 1 Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Cell Transformation, Neoplastic; Everolimus; Humans; Indoles; Kidney Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sirolimus; Sorafenib; Sunitinib; Von Hippel-Lindau Tumor Suppressor Protein	2010
[Angiogenesis inhibition: review of the activity of sorafenib, sunitinib and bevacizumab]. Bulletin du cancer, 2010, Volume: 97 Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sorafenib; Sunitinib; Treatment Outcome	2010
[Antiangionic drugs in soft tissue sarcoma]. Bulletin du cancer, 2010, Volume: 97, Issue:6 Topics: Angiogenesis Inhibitors; Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Doxorubicin; Humans; Indazoles; Indoles; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Pyridines; Pyrimidines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sarcoma; Soft Tissue Neoplasms; Sorafenib; Sulfonamides; Sunitinib; Vascular Endothelial Growth Factor A	2010
Molecular targeted therapy for advanced hepatocellular carcinoma: current status and future perspectives. Journal of gastroenterology, 2010, Volume: 45, Issue:8 Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Drug Delivery Systems; Humans; Liver Neoplasms; Molecular Targeted Therapy; Neovascularization, Pathologic; Niacinamide; Patient Selection; Phenylurea Compounds; Pyridines; Sorafenib; Vascular Endothelial Growth Factor A	2010
Angiogenesis as a therapeutic target in urothelial carcinoma. Anti-cancer drugs, 2010, Volume: 21, Issue:10 Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Humans; Indoles; Matrix Metalloproteinases; Neoadjuvant Therapy; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Rats; Sorafenib; Sunitinib; Survival Rate; Treatment Outcome; Urinary Bladder; Urinary Bladder Neoplasms; Urothelium; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-1; Xenograft Model Antitumor Assays	2010
Antiangiogenic therapy for breast cancer. Breast cancer research : BCR, 2010, Volume: 12, Issue:5 Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Breast Neoplasms; Female; Humans; Indoles; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sorafenib; Sunitinib; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A	2010
In pursuit of new anti-angiogenic therapies for cancer treatment. Frontiers in bioscience (Landmark edition), 2011, 01-01, Volume: 16, Issue:3 Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Drug Resistance, Neoplasm; Humans; Indazoles; Indoles; Neoplasms; Neovascularization, Pathologic; Niacinamide; Oligonucleotides; Phenylurea Compounds; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Sorafenib; Sulfonamides; Sunitinib; Tumor Microenvironment	2011
Therapeutic advances in women's cancers. Frontiers in bioscience (Scholar edition), 2011, 01-01, Volume: 3, Issue:1 Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Cetuximab; ErbB Receptors; Female; Genital Neoplasms, Female; Humans; Indoles; Intestinal Perforation; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Poly(ADP-ribose) Polymerase Inhibitors; Protein-Tyrosine Kinases; PTEN Phosphohydrolase; Pyridines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sunitinib; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A	2011
[Novelties in the treatment for advanced renal-cell cancer]. Orvosi hetilap, 2011, Apr-24, Volume: 152, Issue:17 Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Everolimus; Humans; Indazoles; Indoles; Kidney Neoplasms; Molecular Targeted Therapy; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sirolimus; Sorafenib; Sulfonamides; Sunitinib; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A	2011
Targeting angiogenesis in esophagogastric adenocarcinoma. The oncologist, 2011, Volume: 16, Issue:6 Topics: Adenocarcinoma; Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Biomarkers, Tumor; Clinical Trials, Phase III as Topic; Disease Models, Animal; Disease-Free Survival; Esophageal Neoplasms; Gene Expression Regulation, Neoplastic; Humans; Indoles; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Polymorphism, Genetic; Protein Kinase Inhibitors; Pyridines; Pyrroles; Randomized Controlled Trials as Topic; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A	2011
Emerging therapies targeting tumor vasculature in multiple myeloma and other hematologic and solid malignancies. Current cancer drug targets, 2011, Volume: 11, Issue:9 Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Benzenesulfonates; Hematologic Neoplasms; Humans; Indoles; Multiple Myeloma; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Phthalazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Sorafenib; Sunitinib; Thalidomide; Vascular Endothelial Growth Factor A; Wnt Signaling Pathway	2011
Clinical experience with antiangiogenic therapy in leukemia. Current cancer drug targets, 2011, Volume: 11, Issue:9 Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Clinical Trials as Topic; Humans; Indoles; Lenalidomide; Leukemia; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Quinazolines; Sorafenib; Staurosporine; Sunitinib; Thalidomide; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A	2011
Tyrosine kinase inhibitors for metastatic renal cell carcinoma. Drug and therapeutics bulletin, 2011, Volume: 49, Issue:11 Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Drug Costs; Humans; Indazoles; Indoles; Kidney Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Practice Guidelines as Topic; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Sorafenib; Sulfonamides; Sunitinib; Vascular Endothelial Growth Factor A	2011
Anti-angiogenic therapy: concept to clinic. Microcirculation (New York, N.Y. : 1994), 2012, Volume: 19, Issue:2 Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Biomarkers, Tumor; Humans; Indoles; Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A	2012
Sorafenib: complexities of Raf-dependent and Raf-independent signaling are now unveiled. Medical molecular morphology, 2011, Volume: 44, Issue:4 Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Drug Synergism; Endoplasmic Reticulum Stress; Humans; Liver Neoplasms; MAP Kinase Signaling System; Myeloid Cell Leukemia Sequence 1 Protein; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-bcl-2; Pyridines; raf Kinases; Sorafenib	2011
Immunology in the clinic review series; focus on cancer: tumour-associated macrophages: undisputed stars of the inflammatory tumour microenvironment. Clinical and experimental immunology, 2012, Volume: 167, Issue:2 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzenesulfonates; Chemotaxis; Clodronic Acid; Cytokines; Dioxoles; Disease Progression; Humans; Immunity, Innate; Inflammation; Liposomes; Macrophages; Mice; Molecular Targeted Therapy; Neoplasm Invasiveness; Neoplasm Proteins; Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Sorafenib; Tetrahydroisoquinolines; Trabectedin; Tumor Escape; Tumor Microenvironment	2012
[Possibilities for inhibiting tumor-induced angiogenesis: results with multi-target tyrosine kinase inhibitors]. Magyar onkologia, 2012, Volume: 56, Issue:1 Topics: Angiogenesis Inhibitors; Animals; Axitinib; Benzenesulfonates; Humans; Imidazoles; Indazoles; Indoles; Neoplasms; Neovascularization, Pathologic; Niacinamide; Oligonucleotides; Phenylurea Compounds; Phthalazines; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Receptor Protein-Tyrosine Kinases; Receptors, Fibroblast Growth Factor; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Sorafenib; Sulfonamides; Sunitinib	2012
Sorafenib for treatment of hepatocellular carcinoma: a systematic review. Digestive diseases and sciences, 2012, Volume: 57, Issue:5 Topics: Antineoplastic Protocols; Benzenesulfonates; Carcinoma, Hepatocellular; Cell Proliferation; Chemoembolization, Therapeutic; Hand-Foot Syndrome; Hepatitis, Viral, Human; Humans; Liver; Liver Cirrhosis; Liver Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; raf Kinases; Randomized Controlled Trials as Topic; Receptor Protein-Tyrosine Kinases; Sorafenib; Treatment Outcome	2012
Sorafenib in non-small cell lung cancer. Expert opinion on investigational drugs, 2012, Volume: 21, Issue:9 Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Non-Small-Cell Lung; Humans; Lung Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Precision Medicine; Protein Kinase Inhibitors; Pyridines; Sorafenib	2012
Current status of hepatocellular carcinoma treatment in Japan: transarterial chemoembolization. Clinical drug investigation, 2012, Aug-08, Volume: 32 Suppl 2 Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Ethiodized Oil; Humans; Japan; Liver Neoplasms; Molecular Targeted Therapy; Neoplasm Staging; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Time Factors	2012
Targeted agents and systemic therapy in hepatocellular carcinoma. Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer, 2013, Volume: 190 Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Benzenesulfonates; Carcinoma, Hepatocellular; ErbB Receptors; Erlotinib Hydrochloride; Humans; Immunotherapy; Liver Neoplasms; Molecular Targeted Therapy; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Quinazolines; Sorafenib; Vascular Endothelial Growth Factor A	2013
[Advances in the study of structural modifications of multi-target anticancer drug sorafenib]. Yao xue xue bao = Acta pharmaceutica Sinica, 2012, Volume: 47, Issue:9 Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Humans; Molecular Structure; Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Structure-Activity Relationship	2012
Raf kinase as a target for anticancer therapeutics. Molecular cancer therapeutics, 2005, Volume: 4, Issue:4 Topics: Animals; Antineoplastic Agents; Apoptosis; Benzenesulfonates; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Proliferation; Enzyme Activation; Enzyme Inhibitors; Extracellular Signal-Regulated MAP Kinases; Humans; Membrane Proteins; Models, Biological; Neovascularization, Pathologic; Niacinamide; Oligonucleotides, Antisense; Phenylurea Compounds; Phosphorylation; Protein Structure, Tertiary; Proto-Oncogene Proteins c-kit; Proto-Oncogene Proteins c-raf; Pyridines; Signal Transduction; Sorafenib; Time Factors; Vascular Endothelial Growth Factor Receptor-2	2005
Angiogenesis and lung cancer: prognostic and therapeutic implications. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, May-10, Volume: 23, Issue:14 Topics: Angiogenesis Inhibitors; Benzenesulfonates; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Humans; Lung; Lung Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Phthalazines; Piperidines; Prognosis; Pyridines; Quinazolines; Randomized Controlled Trials as Topic; Sorafenib	2005
Targeting angiogenesis with vascular endothelial growth factor receptor small-molecule inhibitors: novel agents with potential in lung cancer. Clinical lung cancer, 2005, Volume: 7 Suppl 1 Topics: Benzenesulfonates; Clinical Trials as Topic; Humans; Indoles; Lung Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Phthalazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A	2005
Update on angiogenesis inhibitors. Current opinion in oncology, 2005, Volume: 17, Issue:6 Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Colorectal Neoplasms; Humans; Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Phthalazines; Piperidines; Pyridines; Quinazolines; Randomized Controlled Trials as Topic; Signal Transduction; Sorafenib; Vascular Endothelial Growth Factor A	2005
Sorafenib. Expert opinion on pharmacotherapy, 2006, Volume: 7, Issue:4 Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Proliferation; Drug Administration Schedule; Humans; Kidney Neoplasms; Liver Neoplasms; Melanoma; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; raf Kinases; Randomized Controlled Trials as Topic; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Sorafenib; Treatment Outcome; Xenograft Model Antitumor Assays	2006
Molecularly targeted therapy in renal cell carcinoma: where do we go from here? Expert review of anticancer therapy, 2006, Volume: 6, Issue:12 Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Case Management; Clinical Trials as Topic; Combined Modality Therapy; Cytokines; Humans; Indoles; Kidney Neoplasms; Neovascularization, Pathologic; Nephrectomy; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sirolimus; Sorafenib; Sunitinib; Treatment Outcome; Vascular Endothelial Growth Factor A	2006
Vascular endothelial growth factor-targeted therapy in renal cell carcinoma: current status and future directions. Clinical cancer research : an official journal of the American Association for Cancer Research, 2007, Feb-15, Volume: 13, Issue:4 Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Clinical Trials as Topic; Humans; Indoles; Kidney Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A	2007
Drug insight: VEGF as a therapeutic target for breast cancer. Nature clinical practice. Oncology, 2007, Volume: 4, Issue:3 Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Breast Neoplasms; Clinical Trials as Topic; Drug Resistance, Neoplasm; ErbB Receptors; Female; Forecasting; Humans; Neoplasm Proteins; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Pyridines; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Vascular Endothelial Growth Factor A	2007
Sorafenib: in advanced renal cancer. Drugs, 2007, Volume: 67, Issue:3 Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Cell Proliferation; Humans; Kidney Neoplasms; MAP Kinase Signaling System; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Pyridines; Randomized Controlled Trials as Topic; Receptor Protein-Tyrosine Kinases; Sorafenib	2007
Angiogenesis in cancer: molecular mechanisms, clinical impact. Langenbeck's archives of surgery, 2007, Volume: 392, Issue:3 Topics: Angiogenesis Inhibitors; Angiogenic Proteins; Benzenesulfonates; Carcinoma, Squamous Cell; Humans; Indoles; Microcirculation; Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sorafenib; Sunitinib	2007
Role of anti-angiogenesis agents in treating NSCLC: focus on bevacizumab and VEGFR tyrosine kinase inhibitors. Current treatment options in oncology, 2007, Volume: 8, Issue:1 Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Enzyme Inhibitors; Humans; Indoles; Lung Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Piperidines; Pyridines; Pyrroles; Quinazolines; Signal Transduction; Sorafenib; Sunitinib; Treatment Outcome; Vascular Endothelial Growth Factor Receptor-1	2007
[Effect of angiogenesis inhibitors on renal cell carcinoma]. Magyar onkologia, 2007, Volume: 51, Issue:2 Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Humans; Indoles; Interferon-alpha; Kidney Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Protein Kinases; Pyridines; Pyrroles; Randomized Controlled Trials as Topic; Receptors, Vascular Endothelial Growth Factor; Sirolimus; Sorafenib; Sunitinib; Survival Analysis; TOR Serine-Threonine Kinases; Treatment Outcome; Vascular Endothelial Growth Factor A	2007
[Oral drugs inhibiting the VEGF pathway]. Bulletin du cancer, 2007, Volume: 94 Spec No Topics: Administration, Oral; Angiogenesis Inhibitors; Animals; Asthenia; Axitinib; Benzenesulfonates; Humans; Hypertension; Imidazoles; Indazoles; Indoles; Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Phthalazines; Piperidines; Proteinuria; Pyridines; Pyrroles; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A	2007
[Angiogenesis and renal cell carcinoma]. Bulletin du cancer, 2007, Volume: 94 Spec No Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Drug Resistance, Neoplasm; Humans; Hypertension; Indoles; Kidney Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Proteinuria; Pyridines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Sorafenib; Sunitinib; Vascular Endothelial Growth Factors	2007
Playing only one instrument may be not enough: limitations and future of the antiangiogenic treatment of cancer. BioEssays : news and reviews in molecular, cellular and developmental biology, 2007, Volume: 29, Issue:11 Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Indoles; Lung Neoplasms; Models, Biological; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A	2007
[Angiogenesis targeting in renal carcinomas]. Bulletin du cancer, 2007, Volume: 94, Issue:7 Suppl Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sirolimus; Sorafenib; Sunitinib	2007
[Renal cell carcinoma and antiangiogenic therapies]. Presse medicale (Paris, France : 1983), 2008, Volume: 37, Issue:4 Pt 2 Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Humans; Indoles; Kidney Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sirolimus; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A	2008
From single- to multi-target drugs in cancer therapy: when aspecificity becomes an advantage. Current medicinal chemistry, 2008, Volume: 15, Issue:5 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Benzenesulfonates; Bevacizumab; Cetuximab; Clinical Trials as Topic; Enzyme Inhibitors; Erlotinib Hydrochloride; Gefitinib; Humans; Imatinib Mesylate; Indoles; Lapatinib; Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Piperazines; Piperidines; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Receptor Protein-Tyrosine Kinases; Sorafenib; Sunitinib; Trastuzumab	2008
Vascular endothelial growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer: a review of recent clinical trials. Reviews on recent clinical trials, 2007, Volume: 2, Issue:2 Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Humans; Indoles; Neovascularization, Pathologic; Niacinamide; Oligonucleotides; Phenylurea Compounds; Phthalazines; Piperidines; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sunitinib; Treatment Outcome	2007

Trials

9 trial(s) available for sorafenib and Angiogenesis, Pathologic

Article	Year
Tumor Microvessel Density as a Prognostic Marker in High-Risk Renal Cell Carcinoma Patients Treated on ECOG-ACRIN E2805. Clinical cancer research : an official journal of the American Association for Cancer Research, 2018, 01-01, Volume: 24, Issue:1 Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Female; Humans; Kidney Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Staging; Neovascularization, Pathologic; Prognosis; Sorafenib; Sunitinib; Tomography, X-Ray Computed	2018
Sorafenib in Hepatopulmonary Syndrome: A Randomized, Double-Blind, Placebo-Controlled Trial. Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society, 2019, Volume: 25, Issue:8 Topics: Biomarkers; Double-Blind Method; Echocardiography; Female; Hepatopulmonary Syndrome; Humans; Male; Middle Aged; Neovascularization, Pathologic; Placebos; Proof of Concept Study; Protein Kinase Inhibitors; Quality of Life; Sorafenib; Treatment Outcome	2019
Translational predictive biomarker analysis of the phase 1b sorafenib and bevacizumab study expansion cohort. Molecular & cellular proteomics : MCP, 2013, Volume: 12, Issue:6 Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Biomarkers, Pharmacological; Cohort Studies; Disease Progression; Drug Administration Schedule; Drug Therapy, Combination; Extracellular Signal-Regulated MAP Kinases; Female; Gene Expression Regulation, Neoplastic; Genital Neoplasms, Female; Humans; Male; Middle Aged; Neovascularization, Pathologic; Niacinamide; Nitric Oxide Synthase Type III; Phenylurea Compounds; Poly(ADP-ribose) Polymerases; Predictive Value of Tests; Proto-Oncogene Proteins c-akt; Signal Transduction; Skin Neoplasms; Sorafenib; Vascular Endothelial Growth Factor Receptor-2	2013
Angiogenic Response following Radioembolization: Results from a Randomized Pilot Study of Yttrium-90 with or without Sorafenib. Journal of vascular and interventional radiology : JVIR, 2016, Volume: 27, Issue:9 Topics: Aged; Angiogenesis Inhibitors; Biomarkers, Tumor; Carcinoma, Hepatocellular; Chicago; Down-Regulation; Embolization, Therapeutic; Female; Humans; Liver Neoplasms; Male; Middle Aged; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Pilot Projects; Platelet-Derived Growth Factor; Prospective Studies; Radiopharmaceuticals; Sorafenib; Time Factors; Treatment Outcome; Yttrium Radioisotopes	2016
Evaluation of KRAS mutations, angiogenic biomarkers, and DCE-MRI in patients with advanced non-small-cell lung cancer receiving sorafenib. Clinical cancer research : an official journal of the American Association for Cancer Research, 2011, Mar-01, Volume: 17, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Benzenesulfonates; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cytokines; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; ErbB Receptors; Female; Genes, ras; Humans; Lung Neoplasms; Magnetic Resonance Angiography; Male; Middle Aged; Mutation; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); Pyridines; ras Proteins; Sorafenib	2011
Dynamic contrast-enhanced magnetic resonance imaging biomarkers predict survival and response in hepatocellular carcinoma patients treated with sorafenib and metronomic tegafur/uracil. Journal of hepatology, 2011, Volume: 55, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Biomarkers; Carcinoma, Hepatocellular; Contrast Media; Feasibility Studies; Female; Humans; Liver Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Predictive Value of Tests; Pyridines; Sorafenib; Tegafur; Uracil; Young Adult	2011
Intermediate and advanced hepatocellular carcinoma treated with the antiangiogenic agent sorafenib. Evaluation with unenhanced and contrast-enhanced ultrasonography. Medical ultrasonography, 2012, Volume: 14, Issue:2 Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Benzenesulfonates; Carcinoma, Hepatocellular; Contrast Media; Female; Humans; Liver Neoplasms; Male; Middle Aged; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Reproducibility of Results; Sensitivity and Specificity; Sorafenib; Treatment Outcome; Ultrasonography	2012
A phase II study of sorafenib in patients with chemo-naive castration-resistant prostate cancer. Annals of oncology : official journal of the European Society for Medical Oncology, 2008, Volume: 19, Issue:4 Topics: Administration, Oral; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Benzenesulfonates; Biomarkers, Tumor; Canada; Cell Proliferation; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Drug Resistance, Neoplasm; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Lymphatic Metastasis; Male; Middle Aged; Neoplasms, Hormone-Dependent; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Prostate-Specific Antigen; Prostatic Neoplasms; Protein Kinase Inhibitors; Pyridines; Sorafenib; Treatment Outcome	2008
Pilot study of DCE-MRI to predict progression-free survival with sorafenib therapy in renal cell carcinoma. Cancer biology & therapy, 2008, Volume: 7, Issue:4 Topics: Adult; Aged; Angiogenesis Inhibitors; Benzenesulfonates; Carcinoma, Renal Cell; Disease Progression; Disease-Free Survival; Female; Humans; Kidney Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Pilot Projects; Proto-Oncogene Proteins c-raf; Pyridines; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Survival Analysis	2008

Other Studies

158 other study(ies) available for sorafenib and Angiogenesis, Pathologic

Article	Year
BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer research, 2004, Oct-01, Volume: 64, Issue:19 Topics: Administration, Oral; Animals; Benzenesulfonates; Cell Line, Tumor; Disease Progression; Female; Humans; MAP Kinase Kinase Kinase 1; MAP Kinase Kinase Kinases; MAP Kinase Signaling System; Mice; Mice, Nude; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Mitogen-Activated Protein Kinases; Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-raf; Pyridines; Receptor Protein-Tyrosine Kinases; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Xenograft Model Antitumor Assays	2004
Biphenyl derivatives incorporating urea unit as novel VEGFR-2 inhibitors: design, synthesis and biological evaluation. Bioorganic & medicinal chemistry, 2014, Jan-01, Volume: 22, Issue:1 Topics: Biphenyl Compounds; Cell Proliferation; Humans; Models, Molecular; Neovascularization, Pathologic; Urea; Vascular Endothelial Growth Factor Receptor-2	2014
5-Benzylidene-2,4-thiazolidenedione derivatives: Design, synthesis and evaluation as inhibitors of angiogenesis targeting VEGR-2. Bioorganic chemistry, 2016, Volume: 67 Topics: Animals; Benzylidene Compounds; Dose-Response Relationship, Drug; Drug Design; Humans; Molecular Structure; Neovascularization, Pathologic; Protein Kinase Inhibitors; Structure-Activity Relationship; Thiazoles; Vascular Endothelial Growth Factor Receptor-2; Zebrafish	2016
Discovery of novel anti-angiogenesis agents. Part 8: Diaryl thiourea bearing 1H-indazole-3-amine as multi-target RTKs inhibitors. European journal of medicinal chemistry, 2017, Dec-01, Volume: 141 Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Discovery; Drug Screening Assays, Antitumor; Human Umbilical Vein Endothelial Cells; Humans; Indazoles; Molecular Docking Simulation; Molecular Structure; Neovascularization, Pathologic; Protein Kinase Inhibitors; Receptor Protein-Tyrosine Kinases; Structure-Activity Relationship; Thiourea	2017
Discovery of novel anti-angiogenesis agents. Part 7: Multitarget inhibitors of VEGFR-2, TIE-2 and EphB4. European journal of medicinal chemistry, 2017, Dec-01, Volume: 141 Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Cell Proliferation; Dose-Response Relationship, Drug; Drug Discovery; Drug Screening Assays, Antitumor; Humans; Molecular Structure; Neovascularization, Pathologic; Protein Kinase Inhibitors; Receptor, EphB4; Receptor, TIE-2; Structure-Activity Relationship; Vascular Endothelial Growth Factor Receptor-2	2017
Exploration of carbamide derived pyrimidine-thioindole conjugates as potential VEGFR-2 inhibitors with anti-angiogenesis effect. European journal of medicinal chemistry, 2020, Aug-15, Volume: 200 Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Humans; Indoles; Molecular Structure; Neovascularization, Pathologic; Protein Kinase Inhibitors; Pyrimidines; Structure-Activity Relationship; Tumor Cells, Cultured; Urea; Vascular Endothelial Growth Factor Receptor-2	2020
Design, synthesis and evaluation of novel thienopyrimidine-based agents bearing diaryl urea functionality as potential inhibitors of angiogenesis. European journal of medicinal chemistry, 2021, Jan-01, Volume: 209 Topics: Angiogenesis Inhibitors; Apoptosis; Cell Line, Tumor; Cell Proliferation; Drug Design; Drug Screening Assays, Antitumor; Humans; Neovascularization, Pathologic; Pyrimidines; Urea; Vascular Endothelial Growth Factor Receptor-2	2021
Discovery of Oral Anticancer 1,2-Bis(hydroxymethyl)benzo[ Journal of medicinal chemistry, 2021, 09-09, Volume: 64, Issue:17 Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Drug Design; Humans; Lung Neoplasms; Mice; Mice, Nude; Neoplasms, Squamous Cell; Neovascularization, Pathologic; Phthalazines; Small Cell Lung Carcinoma; Structure-Activity Relationship; Xenograft Model Antitumor Assays	2021
Chlorinated benzothiadiazines inhibit angiogenesis through suppression of VEGFR2 phosphorylation. Bioorganic & medicinal chemistry, 2022, 08-01, Volume: 67 Topics: Angiogenesis Inhibitors; Benzothiadiazines; Cell Movement; Cell Proliferation; Human Umbilical Vein Endothelial Cells; Humans; Neovascularization, Pathologic; Phosphorylation; Protein-Tyrosine Kinases; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2	2022
The role of daurisoline treatment in hepatocellular carcinoma: Inhibiting vasculogenic mimicry formation and enhancing sensitivity to sorafenib. Phytomedicine : international journal of phytotherapy and phytopharmacology, 2021, Volume: 92 Topics: Animals; Benzylisoquinolines; Carcinoma, Hepatocellular; Cell Line, Tumor; Humans; Liver Neoplasms; Mice; Neovascularization, Pathologic; Sorafenib	2021
Evaluating the Effect of Lenvatinib on Sorafenib-Resistant Hepatocellular Carcinoma Cells. International journal of molecular sciences, 2021, Dec-02, Volume: 22, Issue:23 Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Cell Proliferation; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; Mice, Inbred BALB C; MicroRNAs; Neovascularization, Pathologic; Phenylurea Compounds; Quinolines; Sorafenib; Xenograft Model Antitumor Assays	2021
Sorafenib inhibits tumor cell growth and angiogenesis in canine transitional cell carcinoma. The Journal of veterinary medical science, 2022, May-17, Volume: 84, Issue:5 Topics: Animals; Antineoplastic Agents; Carcinoma, Transitional Cell; Cell Line, Tumor; Dog Diseases; Dogs; Fibrosarcoma; Mice; Mice, Nude; Neovascularization, Pathologic; Niacinamide; Rodent Diseases; Sorafenib; Tumor Microenvironment; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2	2022
N4BP3 promotes angiogenesis in hepatocellular carcinoma by binding with KAT2B. Cancer science, 2022, Volume: 113, Issue:10 Topics: Angiogenesis Inducing Agents; Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Histones; Humans; Liver Neoplasms; Lysine Acetyltransferases; Mice; Mice, Nude; Neovascularization, Pathologic; Oxygen; Sorafenib; STAT3 Transcription Factor	2022
PLGA-graphene quantum dot nanocomposites targeted against α Biomaterials advances, 2022, Volume: 137 Topics: Graphite; Humans; Integrin beta3; Ligands; Nanocomposites; Neovascularization, Pathologic; Polylactic Acid-Polyglycolic Acid Copolymer; Quantum Dots; Sorafenib	2022
MYBL1 induces transcriptional activation of ANGPT2 to promote tumor angiogenesis and confer sorafenib resistance in human hepatocellular carcinoma. Cell death & disease, 2022, 08-20, Volume: 13, Issue:8 Topics: Adaptor Proteins, Signal Transducing; Angiopoietin-2; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Intracellular Signaling Peptides and Proteins; Liver Neoplasms; Neovascularization, Pathologic; Protein-Arginine N-Methyltransferases; Proto-Oncogene Proteins; Sorafenib; Trans-Activators; Transcriptional Activation	2022
[Sorafenib regulates vascular endothelial growth factor by runt-related transcription factor-3 to inhibit angiogenesis in hepatocellular carcinoma]. Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2022, Jul-20, Volume: 30, Issue:7 Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Core Binding Factor Alpha 3 Subunit; Humans; Liver Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Sorafenib; Vascular Endothelial Growth Factor A	2022
Resistance to tyrosine kinase inhibitors promotes renal cancer progression through MCPIP1 tumor-suppressor downregulation and c-Met activation. Cell death & disease, 2022, 09-22, Volume: 13, Issue:9 Topics: Cadherins; Carcinoma, Renal Cell; Cell Line, Tumor; Down-Regulation; Drug Resistance, Neoplasm; Humans; Interleukin-6; Interleukin-8; Kidney; Kidney Neoplasms; Matrix Metalloproteinase 9; Neovascularization, Pathologic; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Ribonucleases; Sorafenib; Sunitinib; Transcription Factors	2022
Revisiting Antiangiogenic Multikinase Inhibitors in the Era of Immune Checkpoint Blockade: The Case of Sorafenib. Cancer research, 2022, 10-17, Volume: 82, Issue:20 Topics: Angiogenesis Inhibitors; Endothelial Cells; Humans; Immune Checkpoint Inhibitors; Immunotherapy; Liver Neoplasms; MAP Kinase Signaling System; Mitogen-Activated Protein Kinase Kinases; Neovascularization, Pathologic; Receptor Protein-Tyrosine Kinases; Sorafenib; Tyrosine	2022
Bioinformatics analysis revealed hub genes and pathways involved in sorafenib resistance in hepatocellular carcinoma. Mathematical biosciences and engineering : MBE, 2019, 07-08, Volume: 16, Issue:6 Topics: Base Sequence; Biomarkers; Biomarkers, Tumor; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Cell Survival; Computational Biology; Disease Progression; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; Neovascularization, Pathologic; Prognosis; Proto-Oncogene Proteins c-akt; Signal Transduction; Sorafenib	2019
Stem-like tumor cells involved in heterogeneous vasculogenesis in breast cancer. Endocrine-related cancer, 2020, Volume: 27, Issue:1 Topics: Actins; Aldehyde Dehydrogenase 1 Family; Angiogenesis Inhibitors; Animals; Cell Differentiation; Cell Line, Tumor; Endothelial Cells; Eye Proteins; Female; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Mice, Inbred BALB C; Mice, Nude; Neoplastic Stem Cells; Neovascularization, Pathologic; Nerve Growth Factors; Serpins; Sorafenib; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays	2020
TMPRSS4 Drives Angiogenesis in Hepatocellular Carcinoma by Promoting HB-EGF Expression and Proteolytic Cleavage. Hepatology (Baltimore, Md.), 2020, Volume: 72, Issue:3 Topics: Angiogenesis Inhibitors; Bacterial Proteins; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Heparin-binding EGF-like Growth Factor; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Liver Neoplasms; Matrix Metalloproteinase 9; Membrane Proteins; Neovascularization, Pathologic; Phosphatidylinositol 3-Kinases; Prognosis; Serine Endopeptidases; Signal Transduction; Sorafenib	2020
Angiogenesis Genotyping and Clinical Outcomes in Patients with Advanced Hepatocellular Carcinoma Receiving Sorafenib: The ALICE-2 Study. Targeted oncology, 2020, Volume: 15, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Hepatocellular; Female; Genotype; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Liver Neoplasms; Male; Middle Aged; Neovascularization, Pathologic; Polymorphism, Single Nucleotide; Prognosis; Retrospective Studies; Sorafenib; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-1	2020
Galectin-3 expression and secretion by tumor-associated macrophages in hypoxia promotes breast cancer progression. Biochemical pharmacology, 2020, Volume: 178 Topics: Adenocarcinoma; Animals; Bevacizumab; Breast Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Clodronic Acid; Coculture Techniques; Disease Progression; Female; Galectin 3; Gene Expression Regulation, Neoplastic; Humans; Hypoxia; Lymphatic Metastasis; Macrophages; Mammary Neoplasms, Experimental; Mice; Mice, Inbred BALB C; Mice, Nude; Neovascularization, Pathologic; NF-kappa B; Pectins; Signal Transduction; Sorafenib	2020
MicroRNA-375 represses tumor angiogenesis and reverses resistance to sorafenib in hepatocarcinoma. Cancer gene therapy, 2021, Volume: 28, Issue:1-2 Topics: Animals; Carcinoma, Hepatocellular; Drug Resistance, Neoplasm; Humans; Liver Neoplasms; Male; Mice; MicroRNAs; Neovascularization, Pathologic; Rats, Sprague-Dawley; Sorafenib	2021
Dynamic Contrast-Enhanced Magnetic Resonance Imaging as Imaging Biomarker for Vascular Normalization Effect of Infigratinib in High-FGFR-Expressing Hepatocellular Carcinoma Xenografts. Molecular imaging and biology, 2021, Volume: 23, Issue:1 Topics: Animals; Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; Carcinoma, Hepatocellular; Cell Proliferation; Contrast Media; Humans; Kinetics; Liver Neoplasms; Magnetic Resonance Imaging; Mice, SCID; Neovascularization, Pathologic; Perfusion; Phenylurea Compounds; Pyrimidines; Receptors, Fibroblast Growth Factor; Sorafenib; Tumor Microenvironment; Xenograft Model Antitumor Assays	2021
Acteoside as a potential therapeutic option for primary hepatocellular carcinoma: a preclinical study. BMC cancer, 2020, Sep-29, Volume: 20, Issue:1 Topics: Animals; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Cell Proliferation; Gene Expression Regulation, Neoplastic; Glucosides; Hep G2 Cells; Humans; Kallikreins; Liver Neoplasms; Mice; Neovascularization, Pathologic; Phenols; Sorafenib; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays	2020
An assay for cancer stem cell-induced angiogenesis on chick chorioallantoic membrane. Cell biology international, 2021, Volume: 45, Issue:4 Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Cell Line, Tumor; Chick Embryo; Chorioallantoic Membrane; Humans; Neoplasms; Neoplastic Stem Cells; Neovascularization, Pathologic; Sorafenib	2021
Predicting HCC Response to Multikinase Inhibitors With In Vivo Cirrhotic Mouse Model for Personalized Therapy. Cellular and molecular gastroenterology and hepatology, 2021, Volume: 11, Issue:5 Topics: Adult; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Hepatocellular; Cell Proliferation; Disease Models, Animal; Female; Humans; Liver Cirrhosis; Liver Neoplasms; Male; Mice; Mice, Inbred NOD; Mice, SCID; Middle Aged; Neovascularization, Pathologic; Phenylurea Compounds; Precision Medicine; Prognosis; Protein Kinase Inhibitors; Quinolines; Sorafenib; Thioacetamide; Tumor Cells, Cultured; Tumor Microenvironment; Xenograft Model Antitumor Assays	2021
Antiangiogenic activity of zinc and zinc-sorafenib combination using the chick chorioallantoic membrane assay: A descriptive study. Journal of cancer research and therapeutics, 2020, Volume: 16, Issue:Supplement Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Chick Embryo; Chorioallantoic Membrane; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Drug Synergism; Humans; Neoplasms; Neovascularization, Pathologic; Pilot Projects; Sorafenib; Zinc	2020
Sorafenib combined with dasatinib therapy inhibits cell viability, migration, and angiogenesis synergistically in hepatocellular carcinoma. Cancer chemotherapy and pharmacology, 2021, Volume: 88, Issue:1 Topics: Carcinoma, Hepatocellular; Cell Line; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Dasatinib; Hep G2 Cells; Human Umbilical Vein Endothelial Cells; Humans; Liver Neoplasms; Neovascularization, Pathologic; Signal Transduction; Sorafenib; Vascular Endothelial Growth Factor A	2021
Sorafenib derivatives-functionalized gold nanoparticles confer protection against tumor angiogenesis and proliferation via suppression of EGFR and VEGFR-2. Experimental cell research, 2021, 09-01, Volume: 406, Issue:1 Topics: Animals; Antineoplastic Agents; Capillary Permeability; Cell Movement; Cell Proliferation; Drug Carriers; ErbB Receptors; Gene Expression Regulation, Neoplastic; Gold; HCT116 Cells; Human Umbilical Vein Endothelial Cells; Humans; Lung Neoplasms; Matrix Metalloproteinase 2; MCF-7 Cells; Melanoma, Experimental; Metal Nanoparticles; Mice; Mice, Inbred BALB C; Mice, Nude; Neovascularization, Pathologic; Proto-Oncogene Proteins c-myc; Skin Neoplasms; Sorafenib; Tumor Burden; Vascular Endothelial Growth Factor Receptor-2; Zonula Occludens-1 Protein	2021
The in vivo antitumor effects of type I-interferon against hepatocellular carcinoma: the suppression of tumor cell growth and angiogenesis. Scientific reports, 2017, 09-22, Volume: 7, Issue:1 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Human Umbilical Vein Endothelial Cells; Humans; Interferon Type I; Liver Neoplasms; Mice; Neovascularization, Pathologic; Sorafenib; Treatment Outcome; Xenograft Model Antitumor Assays	2017
Use of Ultrasmall Superparamagnetic Iron Oxide Enhanced Susceptibility Weighted Imaging and Mean Vessel Density Imaging to Monitor Antiangiogenic Effects of Sorafenib on Experimental Hepatocellular Carcinoma. Contrast media & molecular imaging, 2017, Volume: 2017 Topics: Angiogenesis Inhibitors; Animals; Carcinoma, Hepatocellular; Ferric Compounds; Heterografts; Humans; Liver Neoplasms; Magnetic Resonance Imaging; Mice; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Sorafenib	2017
Arid1a regulates response to anti-angiogenic therapy in advanced hepatocellular carcinoma. Journal of hepatology, 2018, Volume: 68, Issue:3 Topics: Angiogenesis Inhibitors; Angiopoietin-2; Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Disease Progression; DNA-Binding Proteins; Gene Expression Regulation, Neoplastic; Genes, Tumor Suppressor; Humans; Liver Neoplasms; Mice; Neoplasm Staging; Neovascularization, Pathologic; Nuclear Proteins; Sorafenib; Transcription Factors	2018
Functional Characterization of VEGF- and FGF-induced Tumor Blood Vessel Models in Human Cancer Xenografts. Anticancer research, 2017, Volume: 37, Issue:12 Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Deoxycytidine; Dose-Response Relationship, Drug; Fibroblast Growth Factors; Gemcitabine; Humans; Immunohistochemistry; Mice; Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Sorafenib; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays	2017
Sorafenib improves alkylating therapy by blocking induced inflammation, invasion and angiogenesis in breast cancer cells. Cancer letters, 2018, 07-01, Volume: 425 Topics: Animals; Antineoplastic Agents, Alkylating; Breast Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Cyclophosphamide; Drug Synergism; Female; Gene Expression Regulation, Neoplastic; Humans; MCF-7 Cells; Mice; Neovascularization, Pathologic; Signal Transduction; Sorafenib; Xenograft Model Antitumor Assays	2018
Monocarboxylate transporters MCT1 and MCT4 are independent prognostic biomarkers for the survival of patients with clear cell renal cell carcinoma and those receiving therapy targeting angiogenesis. Urologic oncology, 2018, Volume: 36, Issue:6 Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Renal Cell; Cohort Studies; Female; Follow-Up Studies; Humans; Indoles; Kidney Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Monocarboxylic Acid Transporters; Muscle Proteins; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Prognosis; Pyrroles; Sorafenib; Sunitinib; Survival Rate; Symporters; Vascular Endothelial Growth Factor A	2018
Multicenter prospective study of angiogenesis polymorphism validation in HCC patients treated with sorafenib. An INNOVATE study protocol. Tumori, 2018, Volume: 104, Issue:6 Topics: Adolescent; Angiopoietin-2; Antineoplastic Agents; Carcinoma, Hepatocellular; Disease-Free Survival; Female; Humans; Hypoxia-Inducible Factor 1; Liver Neoplasms; Male; Neovascularization, Pathologic; Nitric Oxide Synthase Type III; Polymorphism, Single Nucleotide; Prospective Studies; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Vascular Endothelial Growth Factor A	2018
[Evaluation of cryptotanshinone inhibition of angiogenesis in human hepatic sinusoidal endothelial cells]. Yao xue xue bao = Acta pharmaceutica Sinica, 2016, Volume: 51, Issue:8 Topics: Animals; Animals, Genetically Modified; Cell Proliferation; Cells, Cultured; Down-Regulation; Drugs, Chinese Herbal; Endothelial Cells; Humans; Neovascularization, Pathologic; Niacinamide; Nitric Oxide; Phenanthrenes; Phenylurea Compounds; Salvia miltiorrhiza; Sorafenib; von Willebrand Factor; Zebrafish	2016
TIP60-dependent acetylation of the SPZ1-TWIST complex promotes epithelial-mesenchymal transition and metastasis in liver cancer. Oncogene, 2019, Volume: 38, Issue:4 Topics: Acetylation; Animals; Basic Helix-Loop-Helix Leucine Zipper Transcription Factors; Bevacizumab; Carcinogenesis; Cell Cycle Proteins; Cell Line, Tumor; Epithelial-Mesenchymal Transition; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; Liver Neoplasms, Experimental; Lysine Acetyltransferase 5; Mice; Mice, Nude; Mice, Transgenic; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Proteins; Neovascularization, Pathologic; Nuclear Proteins; Protein Interaction Mapping; Protein Processing, Post-Translational; Proto-Oncogene Mas; Signal Transduction; Sorafenib; Transcription Factors; Twist-Related Protein 1; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays	2019
The novel PI3K inhibitor S1 synergizes with sorafenib in non-small cell lung cancer cells involving the Akt-S6 signaling. Investigational new drugs, 2019, Volume: 37, Issue:5 Topics: Animals; Apoptosis; Benzamides; Carcinoma, Non-Small-Cell Lung; Cell Movement; Cell Proliferation; Drug Therapy, Combination; Humans; Lung Neoplasms; Male; MAP Kinase Signaling System; Mice; Mice, Inbred BALB C; Mice, Nude; Neovascularization, Pathologic; Phosphatidylinositol 3-Kinases; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Ribosomal Protein S6 Kinases; Sorafenib; Tumor Cells, Cultured; Xenograft Model Antitumor Assays	2019
Comparison of dynamic contrast-enhanced magnetic resonance imaging and contrast-enhanced ultrasound for evaluation of the effects of sorafenib in a rat model of hepatocellular carcinoma. Magnetic resonance imaging, 2019, Volume: 57 Topics: Animals; Biomarkers, Tumor; Capillary Permeability; Carcinoma, Hepatocellular; Cell Line, Tumor; Contrast Media; Disease Models, Animal; Hypoxia; Image Processing, Computer-Assisted; Liver Neoplasms; Magnetic Resonance Imaging; Male; Necrosis; Neovascularization, Pathologic; Permeability; Rats; Sorafenib	2019
Distribution and Activity of Lenvatinib in Brain Tumor Models of Human Anaplastic Thyroid Cancer Cells in Severe Combined Immune Deficient Mice. Molecular cancer therapeutics, 2019, Volume: 18, Issue:5 Topics: Angiogenesis Inhibitors; Animals; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Disease Models, Animal; Heterografts; Humans; Mice; Neoplasm Metastasis; Neovascularization, Pathologic; Phenylurea Compounds; Protein Kinase Inhibitors; Quinolines; Sorafenib; Thyroid Carcinoma, Anaplastic	2019
Preclinical comparison of regorafenib and sorafenib efficacy for hepatocellular carcinoma using multimodality molecular imaging. Cancer letters, 2019, 07-01, Volume: 453 Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Survival; Human Umbilical Vein Endothelial Cells; Humans; Immunohistochemistry; Liver Neoplasms; Mice; Molecular Imaging; Neovascularization, Pathologic; Phenylurea Compounds; Pyridines; Sorafenib; Xenograft Model Antitumor Assays	2019
Short-Term Oral Sorafenib for Therapy of Intratumoral Shunts of Hepatocellular Carcinoma to Enable Intraarterial Treatment. Cardiovascular and interventional radiology, 2019, Volume: 42, Issue:10 Topics: Aged; Aged, 80 and over; Angiography, Digital Subtraction; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Female; Humans; Infusions, Intra-Arterial; Liver; Liver Neoplasms; Male; Neovascularization, Pathologic; Retrospective Studies; Sorafenib; Time; Tomography, X-Ray Computed; Treatment Outcome	2019
Sorafenib delays recurrence and metastasis after liver transplantation in a rat model of hepatocellular carcinoma with high expression of phosphorylated extracellular signal-regulated kinase. Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society, 2013, Volume: 19, Issue:5 Topics: Animals; Apoptosis; Disease Models, Animal; Disease-Free Survival; Extracellular Signal-Regulated MAP Kinases; Liver Neoplasms, Experimental; Liver Transplantation; Male; Neoplasm Recurrence, Local; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Phosphorylation; Protein Kinase Inhibitors; Rats; Rats, Inbred ACI; Rats, Inbred Lew; Sorafenib; Tissue Array Analysis	2013
The Combination of Sorafenib and Everolimus Abrogates mTORC1 and mTORC2 upregulation in osteosarcoma preclinical models. Clinical cancer research : an official journal of the American Association for Cancer Research, 2013, Apr-15, Volume: 19, Issue:8 Topics: AMP-Activated Protein Kinases; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Cell Cycle; Cell Survival; Chick Embryo; Everolimus; Female; Flow Cytometry; Humans; Immunohistochemistry; Mechanistic Target of Rapamycin Complex 1; Mechanistic Target of Rapamycin Complex 2; Mice; Mice, Inbred NOD; Mice, SCID; Multiprotein Complexes; Neovascularization, Pathologic; Niacinamide; Osteosarcoma; Phenylurea Compounds; Reactive Oxygen Species; RNA Interference; Sirolimus; Sorafenib; TOR Serine-Threonine Kinases; Up-Regulation; Xenograft Model Antitumor Assays	2013
Assessment of response to sorafenib in advanced hepatocellular carcinoma using perfusion computed tomography: results of a pilot study. Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2013, Volume: 45, Issue:9 Topics: Aged; Aged, 80 and over; alpha-Fetoproteins; Antineoplastic Agents; Carcinoma, Hepatocellular; Cohort Studies; Feasibility Studies; Female; Humans; Liver; Liver Neoplasms; Male; Middle Aged; Multidetector Computed Tomography; Neovascularization, Pathologic; Niacinamide; Perfusion Imaging; Phenylurea Compounds; Pilot Projects; Prospective Studies; Regional Blood Flow; Sorafenib; Treatment Outcome	2013
The evolving landscape of therapeutic drug development for hepatocellular carcinoma. Contemporary clinical trials, 2013, Volume: 36, Issue:2 Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Drug Therapy, Combination; Epigenesis, Genetic; ErbB Receptors; Fibroblast Growth Factors; Humans; Liver Neoplasms; Neovascularization, Pathologic; Niacinamide; Oncogene Protein v-akt; Phenylurea Compounds; Phosphoinositide-3 Kinase Inhibitors; Proto-Oncogene Proteins c-met; Signal Transduction; Sorafenib; TOR Serine-Threonine Kinases	2013
Sorafenib inhibits lymphoma xenografts by targeting MAPK/ERK and AKT pathways in tumor and vascular cells. PloS one, 2013, Volume: 8, Issue:4 Topics: Angiogenesis Inhibitors; Animals; Apoptosis; Cell Count; Cell Line, Tumor; Cell Proliferation; Cell Survival; Endothelial Cells; Extracellular Signal-Regulated MAP Kinases; Humans; Lymphoma; MAP Kinase Signaling System; Mice; Mice, SCID; Necrosis; Neovascularization, Pathologic; Niacinamide; Pericytes; Phenylurea Compounds; Phosphatidylinositol 3-Kinases; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Sorafenib; Xenograft Model Antitumor Assays	2013
Impact of tumor vascularity on responsiveness to antiangiogenesis in a prostate cancer stem cell-derived tumor model. Molecular cancer therapeutics, 2013, Volume: 12, Issue:5 Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Apoptosis; Axitinib; Cell Line, Tumor; Disease Models, Animal; Humans; Hypoxia; Imidazoles; Indazoles; Male; Neoplastic Stem Cells; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Prostatic Neoplasms; Protein Kinase Inhibitors; Sorafenib; Xenograft Model Antitumor Assays	2013
Antiangiogenic therapy promoted metastasis of hepatocellular carcinoma by suppressing host-derived interleukin-12b in mouse models. Angiogenesis, 2013, Volume: 16, Issue:4 Topics: Angiogenesis Inhibitors; Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Dendritic Cells; Diphosphonates; Heterografts; Humans; Imidazoles; Immunosuppression Therapy; Indoles; Interleukin-12 Subunit p40; Killer Cells, Natural; Liver Neoplasms; Lung Neoplasms; Macrophages; Male; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Knockout; Mice, Nude; Neoplasm Transplantation; Neoplastic Cells, Circulating; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sunitinib; Zoledronic Acid	2013
Concurrent versus sequential sorafenib therapy in combination with radiation for hepatocellular carcinoma. PloS one, 2013, Volume: 8, Issue:6 Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Cycle; Cell Line, Tumor; Clinical Trials as Topic; Combined Modality Therapy; DNA Breaks, Double-Stranded; Gamma Rays; Gene Expression; Hindlimb; Histones; Humans; Liver Neoplasms; Mice; Mice, Nude; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Radiation Tolerance; Sorafenib; Tumor Burden; Xenograft Model Antitumor Assays	2013
Survey of activated kinase proteins reveals potential targets for cholangiocarcinoma treatment. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2013, Volume: 34, Issue:6 Topics: Angiogenesis Inhibitors; Apoptosis; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Blotting, Western; Cell Communication; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cholangiocarcinoma; Enzyme Activation; Humans; Indoles; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein Kinases; Proto-Oncogene Proteins c-akt; Pyrroles; Signal Transduction; Sorafenib; Sunitinib	2013
Pretherapeutic drug evaluation by tumor xenografting in anaplastic thyroid cancer. The Journal of surgical research, 2013, Volume: 185, Issue:2 Topics: Animals; Apoptosis; Benzazepines; Cell Proliferation; Drug Evaluation, Preclinical; Humans; Male; Mice; Mice, Nude; Middle Aged; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Quinazolines; Random Allocation; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Thyroid Carcinoma, Anaplastic; Thyroid Neoplasms; Treatment Outcome; Xenograft Model Antitumor Assays	2013
Pro-angiogenic cytokines for prediction of outcomes in patients with advanced hepatocellular carcinoma. British journal of cancer, 2013, Oct-15, Volume: 109, Issue:8 Topics: Adult; Aged; Aged, 80 and over; Angiopoietin-2; Antineoplastic Agents; Carcinoma, Hepatocellular; Cohort Studies; Cytokines; Female; Humans; Liver Neoplasms; Male; Middle Aged; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Retrospective Studies; Sorafenib	2013
Combination of sorafenib and angiotensin-II receptor blocker attenuates preneoplastic lesion development in a non-diabetic rat model of steatohepatitis. Journal of gastroenterology, 2014, Volume: 49, Issue:10 Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Anticarcinogenic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cell Proliferation; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Hep G2 Cells; Humans; Liver Neoplasms, Experimental; Losartan; Male; Neovascularization, Pathologic; Niacinamide; Non-alcoholic Fatty Liver Disease; Phenylurea Compounds; Precancerous Conditions; Rats, Inbred F344; Sorafenib	2014
The role of receptor tyrosine kinase activation in cholangiocytes and pulmonary vascular endothelium in experimental hepatopulmonary syndrome. American journal of physiology. Gastrointestinal and liver physiology, 2014, Jan-01, Volume: 306, Issue:1 Topics: Animals; Common Bile Duct; Disease Models, Animal; Endothelin-1; Endothelium, Vascular; Hepatopulmonary Syndrome; Ligation; Lung; Male; Neovascularization, Pathologic; Niacinamide; Nitric Oxide Synthase Type III; Phenylurea Compounds; Protein Kinase Inhibitors; Rats; Rats, Sprague-Dawley; Receptor Protein-Tyrosine Kinases; Signal Transduction; Sorafenib; Vascular Endothelial Growth Factor A	2014
SL1122-37, a novel derivative of sorafenib, has greater effects than sorafenib on the inhibition of human hepatocellular carcinoma (HCC) growth and prevention of angiogenesis. Bioscience trends, 2013, Volume: 7, Issue:5 Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Colorimetry; Human Umbilical Vein Endothelial Cells; Humans; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Sorafenib	2013
Tyrosine kinase inhibitor-induced vasculopathy in clear cell renal cell carcinoma: an unrecognized antitumour mechanism. Histopathology, 2014, Volume: 64, Issue:4 Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Neovascularization, Pathologic; Nephrectomy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Retrospective Studies; Sorafenib; Sunitinib	2014
Pancreatic cancer: Sorafenib: no effect on efficacy of chemotherapy in pancreatic cancer. Nature reviews. Gastroenterology & hepatology, 2014, Volume: 11, Issue:1 Topics: Adenocarcinoma; Antineoplastic Agents; Cisplatin; Deoxycytidine; Drug Therapy, Combination; Gemcitabine; Humans; Neovascularization, Pathologic; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Sorafenib; Treatment Outcome	2014
Olmesartan potentiates the anti-angiogenic effect of sorafenib in mice bearing Ehrlich's ascites carcinoma: role of angiotensin (1-7). PloS one, 2014, Volume: 9, Issue:1 Topics: Angiotensin I; Angiotensin II Type 1 Receptor Blockers; Animals; Antineoplastic Agents; Carcinoma, Ehrlich Tumor; Dose-Response Relationship, Drug; Down-Regulation; Drug Synergism; Female; Imidazoles; Immunohistochemistry; Insulin-Like Growth Factor I; Mice; Neovascularization, Pathologic; Niacinamide; Peptide Fragments; Phenylurea Compounds; Receptor, IGF Type 1; Sorafenib; Tetrazoles; Tumor Burden; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2	2014
Simultaneous inhibition of tumor growth and angiogenesis for resistant hepatocellular carcinoma by co-delivery of sorafenib and survivin small hairpin RNA. Molecular pharmaceutics, 2014, Oct-06, Volume: 11, Issue:10 Topics: Animals; Carcinoma, Hepatocellular; Cell Cycle; Drug Resistance, Neoplasm; Humans; Inhibitor of Apoptosis Proteins; Liver Neoplasms; Male; Mice; Mice, Inbred BALB C; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Repressor Proteins; RNA, Small Interfering; Sorafenib; Survivin	2014
VEGF and VEGFR genotyping in the prediction of clinical outcome for HCC patients receiving sorafenib: the ALICE-1 study. International journal of cancer, 2014, Sep-01, Volume: 135, Issue:5 Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Proliferation; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Genotype; Humans; Liver Neoplasms; Lymphangiogenesis; Male; Middle Aged; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Polymorphism, Single Nucleotide; Protein Kinase Inhibitors; Retrospective Studies; Sorafenib; Treatment Outcome; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor C; Vascular Endothelial Growth Factor Receptor-1; Vascular Endothelial Growth Factor Receptor-2; Vascular Endothelial Growth Factor Receptor-3	2014
Treatment of collecting duct carcinoma: current status and future perspectives. Anticancer research, 2014, Volume: 34, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Renal Cell; Cohort Studies; Humans; Indazoles; Kidney Neoplasms; Middle Aged; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Pyrimidines; Sirolimus; Sorafenib; Sulfonamides	2014
Effect of BZG-4000, a novel multi-targeted kinase inhibitor with potent anticancer activity, on a hepatocellular carcinoma xenograft model. Scientific reports, 2014, Mar-17, Volume: 4 Topics: Administration, Oral; Angiogenesis Inhibitors; Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Drug Administration Schedule; Gene Expression; Hepatocytes; Humans; Liver Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Platelet Endothelial Cell Adhesion Molecule-1; Protein Kinase Inhibitors; Sorafenib; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays	2014
The relevance of testing the efficacy of anti-angiogenesis treatments on cells derived from primary tumors: a new method for the personalized treatment of renal cell carcinoma. PloS one, 2014, Volume: 9, Issue:3 Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Basic Helix-Loop-Helix Leucine Zipper Transcription Factors; Carcinoma, Renal Cell; Disease Models, Animal; Drug Resistance, Neoplasm; Female; Gene Expression; Humans; Indoles; Kidney Neoplasms; Mice; Molecular Targeted Therapy; Neoplasm Metastasis; Neoplasm Staging; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Precision Medicine; Pyrroles; Receptor Protein-Tyrosine Kinases; Sorafenib; Sunitinib; Tumor Cells, Cultured; Xenograft Model Antitumor Assays	2014
A preclinical evaluation of a novel multikinase inhibitor, SKLB-329, as a therapeutic agent against hepatocellular carcinoma. International journal of cancer, 2014, Dec-15, Volume: 135, Issue:12 Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Drug Evaluation, Preclinical; Endothelial Cells; Female; Human Umbilical Vein Endothelial Cells; Humans; Inhibitory Concentration 50; Liver; Liver Neoplasms; Mice; Mice, Inbred BALB C; Neoplasm Transplantation; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrazoles; Signal Transduction; Sorafenib; Zebrafish	2014
Evaluation of the impact of transient interruption of antiangiogenic treatment using ultrasound-based techniques in a murine model of hepatocellular carcinoma. BMC cancer, 2014, Jun-04, Volume: 14 Topics: Angiogenesis Inhibitors; Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Disease Models, Animal; Humans; Liver Neoplasms; Mice; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Sorafenib; Ultrasonography; Vascular Endothelial Growth Factor Receptor-2	2014
Therapeutic effects of artesunate in hepatocellular carcinoma: repurposing an ancient antimalarial agent. European journal of gastroenterology & hepatology, 2014, Volume: 26, Issue:8 Topics: Animals; Antineoplastic Agents; Artemisinins; Artesunate; Carcinoma, Hepatocellular; Cell Death; Dose-Response Relationship, Drug; Drug Repositioning; Drug Resistance, Neoplasm; Drug Therapy, Combination; Humans; Liver Neoplasms; Liver Neoplasms, Experimental; Male; Mice; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Sorafenib; Treatment Outcome; Tumor Cells, Cultured; Unfolded Protein Response	2014
The combination of HTATIP2 expression and microvessel density predicts converse survival of hepatocellular carcinoma with or without sorafenib. Oncotarget, 2014, Jun-15, Volume: 5, Issue:11 Topics: Acetyltransferases; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Microvessels; Middle Aged; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Prognosis; Sorafenib; Transcription Factors; Young Adult	2014
Both sunitinib and sorafenib are effective treatments for pheochromocytoma in a xenograft model. Cancer letters, 2014, Oct-01, Volume: 352, Issue:2 Topics: Administration, Oral; Adrenal Gland Neoplasms; Angiogenesis Inhibitors; Animals; Apoptosis; Cell Survival; Dose-Response Relationship, Drug; Heterografts; Indoles; Male; Mice; Mice, Nude; Neoplasm Transplantation; Neovascularization, Pathologic; Niacinamide; PC12 Cells; Phenylurea Compounds; Pheochromocytoma; Protein Kinase Inhibitors; Pyrroles; Rats; Sorafenib; Sunitinib; Time Factors; Tumor Burden	2014
Blocking lipid synthesis overcomes tumor regrowth and metastasis after antiangiogenic therapy withdrawal. Cell metabolism, 2014, Aug-05, Volume: 20, Issue:2 Topics: Angiogenesis Inhibitors; Animals; Cell Line, Tumor; Disease Progression; Fatty Acid Synthases; Homeodomain Proteins; Humans; Indoles; Lipids; Metabolomics; Mice; Mice, Inbred C57BL; Mice, Knockout; Neoplasm Metastasis; Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Proteomics; Pyrroles; RNA Interference; Sorafenib; Sunitinib; Transplantation, Heterologous	2014
Use of VEGFR-2 targeted ultrasound contrast agent for the early evaluation of response to sorafenib in a mouse model of hepatocellular carcinoma. Molecular imaging and biology, 2015, Volume: 17, Issue:1 Topics: Angiogenesis Inhibitors; Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Contrast Media; Humans; Liver Neoplasms; Mice; Microbubbles; Neoplasm Transplantation; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Random Allocation; Software; Sorafenib; Treatment Outcome; Ultrasonography; Vascular Endothelial Growth Factor Receptor-2	2015
2-Methoxyestradiol synergizes with sorafenib to suppress hepatocellular carcinoma by simultaneously dysregulating hypoxia-inducible factor-1 and -2. Cancer letters, 2014, Dec-01, Volume: 355, Issue:1 Topics: 2-Methoxyestradiol; Active Transport, Cell Nucleus; Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Basic Helix-Loop-Helix Transcription Factors; Carcinoma, Hepatocellular; Cell Proliferation; Cyclin D1; Dose-Response Relationship, Drug; Drug Synergism; Estradiol; Hep G2 Cells; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Isoenzymes; L-Lactate Dehydrogenase; Lactate Dehydrogenase 5; Liver Neoplasms; Male; Mice, Inbred BALB C; Mice, Nude; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; RNA Interference; Signal Transduction; Sorafenib; Time Factors; Transfection; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays	2014
The mechanisms responsible for the radiosensitizing effects of sorafenib on colon cancer cells. Oncology reports, 2014, Volume: 32, Issue:6 Topics: Cell Cycle; Cell Line, Tumor; Cell Movement; Cell Proliferation; Colorectal Neoplasms; DNA Damage; Humans; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Radiation Tolerance; Radiation-Sensitizing Agents; Sorafenib	2014
Anti-tumor activity of sorafenib in a model of a pediatric hepatocellular carcinoma. Experimental cell research, 2015, Feb-01, Volume: 331, Issue:1 Topics: Adult; Animals; beta Catenin; Blotting, Western; Carcinoma, Hepatocellular; Cell Proliferation; Child; Epithelial-Mesenchymal Transition; Female; Humans; Liver Neoplasms; Male; Mice; Mice, Inbred NOD; Mice, SCID; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Tumor Cells, Cultured; Xenograft Model Antitumor Assays	2015
NSK-01105, a novel sorafenib derivative, inhibits human prostate tumor growth via suppression of VEGFR2/EGFR-mediated angiogenesis. PloS one, 2014, Volume: 9, Issue:12 Topics: Angiogenesis Inhibitors; Animals; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Drug Discovery; Enzyme Activation; ErbB Receptors; Human Umbilical Vein Endothelial Cells; Humans; Male; Mice; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Prostatic Neoplasms; Quinazolines; Signal Transduction; Sorafenib; Vascular Endothelial Growth Factor Receptor-2; Xenograft Model Antitumor Assays	2014
Codelivery of sorafenib and curcumin by directed self-assembled nanoparticles enhances therapeutic effect on hepatocellular carcinoma. Molecular pharmaceutics, 2015, Mar-02, Volume: 12, Issue:3 Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biopharmaceutics; Cell Line, Tumor; Cell Proliferation; Curcumin; Drug Delivery Systems; Hep G2 Cells; Humans; Liver Neoplasms, Experimental; Mice; Nanoparticles; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Sorafenib; Tissue Distribution; Xenograft Model Antitumor Assays	2015
Evaluation of in vivo responses of sorafenib therapy in a preclinical mouse model of PTEN-deficient of prostate cancer. Journal of translational medicine, 2015, May-08, Volume: 13 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Proliferation; Disease Models, Animal; Everolimus; Genetic Engineering; Homozygote; Immunohistochemistry; In Situ Nick-End Labeling; Male; Mice; Mice, Knockout; Neoplasms, Experimental; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Prostatic Neoplasms; PTEN Phosphohydrolase; Signal Transduction; Sorafenib	2015
Model Matters: Differences in Orthotopic Rat Hepatocellular Carcinoma Physiology Determine Therapy Response to Sorafenib. Clinical cancer research : an official journal of the American Association for Cancer Research, 2015, Oct-01, Volume: 21, Issue:19 Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Biomarkers; Biopsy; Carcinoma, Hepatocellular; Cell Transformation, Neoplastic; Comparative Genomic Hybridization; Disease Models, Animal; Immunohistochemistry; Liver Neoplasms; Liver Neoplasms, Experimental; Magnetic Resonance Imaging; Male; Neoplasm Grading; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Rats; Sorafenib	2015
Efficacy of perifosine alone and in combination with sorafenib in an HrasG12V plus shp53 transgenic mouse model of hepatocellular carcinoma. Cancer chemotherapy and pharmacology, 2015, Volume: 76, Issue:2 Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Hepatocellular; Caspase 3; Caspase 9; Cell Proliferation; DNA Transposable Elements; Drug Synergism; Liver Neoplasms, Experimental; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Phosphorylcholine; Poly(ADP-ribose) Polymerases; Proto-Oncogene Proteins p21(ras); RNA, Small Interfering; Sorafenib; Tumor Suppressor Protein p53	2015
1118-20, an indazole diarylurea compound, inhibits hepatocellular carcinoma HepG2 proliferation and tumour angiogenesis involving Wnt/β-catenin pathway and receptor tyrosine kinases. The Journal of pharmacy and pharmacology, 2015, Volume: 67, Issue:10 Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Movement; Cell Proliferation; Hep G2 Cells; Human Umbilical Vein Endothelial Cells; Humans; Indazoles; Liver Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Receptor Protein-Tyrosine Kinases; Sorafenib; Wnt Signaling Pathway	2015
Inhibition of MAPK and VEGFR by Sorafenib Controls the Progression of Endometriosis. Reproductive sciences (Thousand Oaks, Calif.), 2015, Volume: 22, Issue:9 Topics: Adult; Animals; Apoptosis; Case-Control Studies; Cell Proliferation; Cells, Cultured; Disease Models, Animal; Disease Progression; Dose-Response Relationship, Drug; Endometriosis; Endometrium; Extracellular Signal-Regulated MAP Kinases; Female; Heterografts; Humans; Mice, Nude; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Phosphorylation; Protein Kinase Inhibitors; Signal Transduction; Sorafenib; Stromal Cells; Time Factors; Vascular Endothelial Growth Factor Receptor-2	2015
Delivery of siRNA Using CXCR4-targeted Nanoparticles Modulates Tumor Microenvironment and Achieves a Potent Antitumor Response in Liver Cancer. Molecular therapy : the journal of the American Society of Gene Therapy, 2015, Volume: 23, Issue:11 Topics: Angiogenesis Inhibitors; Animals; Benzylamines; Carcinoma, Hepatocellular; Cell Line, Tumor; Chemokine CXCL12; Cyclams; Disease Progression; Genetic Therapy; Heterocyclic Compounds; Humans; Liver Neoplasms; Male; Mice; Mice, Inbred C3H; Nanoparticles; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Receptors, CXCR4; RNA, Small Interfering; Signal Transduction; Sorafenib; Tumor Microenvironment; Vascular Endothelial Growth Factor A	2015
Incomplete Dll4/Notch signaling inhibition promotes functional angiogenesis supporting the growth of skin papillomas. BMC cancer, 2015, Aug-28, Volume: 15 Topics: Adaptor Proteins, Signal Transducing; Animals; Antineoplastic Agents; Calcium-Binding Proteins; Disease Progression; Down-Regulation; Gene Deletion; Intracellular Signaling Peptides and Proteins; Male; Membrane Proteins; Mice; Neovascularization, Pathologic; Niacinamide; Papilloma; Phenylurea Compounds; Real-Time Polymerase Chain Reaction; Signal Transduction; Skin Neoplasms; Sorafenib; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-1; Vascular Endothelial Growth Factor Receptor-2	2015
CXCR2 Inhibition Combined with Sorafenib Improved Antitumor and Antiangiogenic Response in Preclinical Models of Ovarian Cancer. PloS one, 2015, Volume: 10, Issue:9 Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Disease Models, Animal; Disease Progression; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Human Umbilical Vein Endothelial Cells; Mice, Nude; Neovascularization, Pathologic; Niacinamide; Ovarian Neoplasms; Phenotype; Phenylurea Compounds; Receptors, Interleukin-8B; Sorafenib; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays	2015
Murine colitis treated with multitargeted tyrosine kinase inhibitors. The Journal of surgical research, 2016, Volume: 200, Issue:2 Topics: Animals; Axitinib; Colitis; Imidazoles; Indazoles; Indoles; Male; Mice; Mice, Inbred C57BL; Microvessels; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrroles; Sorafenib; Sunitinib; Treatment Outcome	2016
DCT015, a new sorafenib derivate, inhibits tumor growth and angiogenesis in gastric cancer models. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2016, Volume: 37, Issue:7 Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Apoptosis; Cell Line; Cell Line, Tumor; Cell Movement; Cell Proliferation; HCT116 Cells; Human Umbilical Vein Endothelial Cells; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Signal Transduction; Sorafenib; Stomach Neoplasms; Tumor Burden	2016
Bufalin enhances anti-angiogenic effect of sorafenib via AKT/VEGF signaling. International journal of oncology, 2016, Volume: 48, Issue:3 Topics: Angiogenesis Inhibitors; Animals; Aorta; Apoptosis; Bufanolides; Cell Cycle; Cell Movement; Cell Proliferation; Cell Survival; Chick Embryo; Cytokines; Drug Synergism; Enzyme Inhibitors; Enzyme-Linked Immunosorbent Assay; Human Umbilical Vein Endothelial Cells; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-akt; Random Allocation; Rats; Signal Transduction; Sorafenib; Vascular Endothelial Growth Factor A	2016
(Secondary) solid tumors in thyroid cancer patients treated with the multi-kinase inhibitor sorafenib may present diagnostic challenges. BMC cancer, 2016, Jan-19, Volume: 16 Topics: Aged; Apoptosis; Carcinogenesis; Carcinoma, Squamous Cell; Female; Humans; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); Sorafenib; Thyroid Neoplasms	2016
Co-option of Liver Vessels and Not Sprouting Angiogenesis Drives Acquired Sorafenib Resistance in Hepatocellular Carcinoma. Journal of the National Cancer Institute, 2016, Volume: 108, Issue:8 Topics: Actins; Animals; Antigens, CD34; Antineoplastic Agents; Blood Vessels; Carcinoma, Hepatocellular; Contrast Media; Disease Models, Animal; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Homeodomain Proteins; Humans; Liver; Liver Neoplasms; Male; Mice; Mice, SCID; MicroRNAs; Neoplasm Invasiveness; Neoplasm Transplantation; Neovascularization, Pathologic; Niacinamide; Osteopontin; Phenylurea Compounds; Repressor Proteins; Sequence Analysis, RNA; Signal Transduction; Sorafenib; Ultrasonography; Up-Regulation; Vascular Endothelial Growth Factor A; Vimentin; Zinc Finger E-box Binding Homeobox 2; Zinc Finger E-box-Binding Homeobox 1	2016
Actionable pathways: interactive discovery of therapeutic targets using signaling pathway models. Nucleic acids research, 2016, 07-08, Volume: 44, Issue:W1 Topics: Antineoplastic Agents; Breast Neoplasms; Computer Graphics; Computer Simulation; Drug Discovery; Gene Expression Regulation, Neoplastic; Gene Knockout Techniques; Humans; Information Storage and Retrieval; Internet; Metabolic Networks and Pathways; Models, Statistical; Molecular Targeted Therapy; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Signal Transduction; Software; Sorafenib	2016
Evaluation of antiangiogenic and antiproliferative effects of sorafenib by sequential histology and intravoxel incoherent motion diffusion-weighted imaging in an orthotopic hepatocellular carcinoma xenograft model. Journal of magnetic resonance imaging : JMRI, 2017, Volume: 45, Issue:1 Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Diffusion Magnetic Resonance Imaging; Image Enhancement; Image Interpretation, Computer-Assisted; Liver Neoplasms; Magnetic Resonance Angiography; Male; Mice; Mice, Inbred BALB C; Motion; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Reproducibility of Results; Sensitivity and Specificity; Sorafenib; Treatment Outcome	2017
Microwave coagulation/ablation in combination with sorafenib suppresses the overgrowth of residual tumor in VX2 liver tumor model. Discovery medicine, 2016, Volume: 21, Issue:118 Topics: Animals; Catheter Ablation; Cell Line, Tumor; Chemotherapy, Adjuvant; Contrast Media; Diffusion Magnetic Resonance Imaging; Immunohistochemistry; Liver; Liver Neoplasms, Experimental; Microwaves; Necrosis; Neoplasm, Residual; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Rabbits; Sorafenib; Ultrasonography	2016
IGF2 Is Up-regulated by Epigenetic Mechanisms in Hepatocellular Carcinomas and Is an Actionable Oncogene Product in Experimental Models. Gastroenterology, 2016, Volume: 151, Issue:6 Topics: Animals; Antibodies, Monoclonal, Humanized; Antibodies, Neutralizing; Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Case-Control Studies; Cell Line, Tumor; Cell Movement; Cell Proliferation; DNA Methylation; Epigenesis, Genetic; Female; Gene Expression; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Insulin-Like Growth Factor II; Liver Neoplasms; Male; Mice, Inbred C57BL; MicroRNAs; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Phosphorylation; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-myc; Receptor, IGF Type 1; Receptors, Somatomedin; RNA, Messenger; RNA, Small Interfering; Signal Transduction; Sorafenib; Tumor Stem Cell Assay; Up-Regulation	2016
Implications of vessel co-option in sorafenib-resistant hepatocellular carcinoma. Chinese journal of cancer, 2016, Nov-25, Volume: 35, Issue:1 Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Drug Resistance, Neoplasm; Humans; Liver Neoplasms; Mice; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Sorafenib	2016
Combination of Everolimus with Sorafenib for Solid Renal Tumors in Tsc2 Neoplasia (New York, N.Y.), 2017, Volume: 19, Issue:2 Topics: Animals; ATP-Binding Cassette Transporters; Cell Death; Cell Line, Tumor; Disease Models, Animal; Drug Synergism; Everolimus; GTPase-Activating Proteins; Kidney Neoplasms; Mice; Mice, Knockout; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Sorafenib; Tuberous Sclerosis	2017
Acquired Resistance with Epigenetic Alterations Under Long-Term Antiangiogenic Therapy for Hepatocellular Carcinoma. Molecular cancer therapeutics, 2017, Volume: 16, Issue:6 Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Disease Models, Animal; DNA Methylation; Drug Resistance, Neoplasm; Epigenesis, Genetic; Gene Expression Profiling; Gene Expression Regulation; Histones; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Mice; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Promoter Regions, Genetic; Sorafenib; Treatment Outcome; Xenograft Model Antitumor Assays	2017
Combining nanoliposomal ceramide with sorafenib synergistically inhibits melanoma and breast cancer cell survival to decrease tumor development. Clinical cancer research : an official journal of the American Association for Cancer Research, 2008, Jun-01, Volume: 14, Issue:11 Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzenesulfonates; Blotting, Western; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Ceramides; Drug Synergism; Humans; Liposomes; Melanoma; Mitogen-Activated Protein Kinases; Nanoparticles; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-akt; Pyridines; Signal Transduction; Sorafenib	2008
Effect of rapamycin alone and in combination with sorafenib in an orthotopic model of human hepatocellular carcinoma. Clinical cancer research : an official journal of the American Association for Cancer Research, 2008, Aug-15, Volume: 14, Issue:16 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzenesulfonates; Blotting, Western; Carcinoma, Hepatocellular; Cell Proliferation; Enzyme-Linked Immunosorbent Assay; Humans; Immunohistochemistry; In Situ Nick-End Labeling; Liver Neoplasms; Male; Mice; Mice, Nude; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Platelet Endothelial Cell Adhesion Molecule-1; Pyridines; Sirolimus; Sorafenib; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays	2008
Tie2 in tumor endothelial signaling and survival: implications for antiangiogenic therapy. Molecular cancer research : MCR, 2009, Volume: 7, Issue:3 Topics: Angiopoietin-1; Animals; Apoptosis; Benzenesulfonates; Doxycycline; Endothelial Cells; Enzyme Activation; Extracellular Signal-Regulated MAP Kinases; Female; Humans; In Vitro Techniques; Melanoma, Experimental; Mice; Mice, Inbred C3H; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-akt; Pyridines; Receptor, TIE-2; Recombinant Proteins; Signal Transduction; Sorafenib; Transfection	2009
Diffuse-type gastric carcinoma: progression, angiogenesis, and transforming growth factor beta signaling. Journal of the National Cancer Institute, 2009, Apr-15, Volume: 101, Issue:8 Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Biomarkers, Tumor; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; Disease Progression; Down-Regulation; Enzyme-Linked Immunosorbent Assay; Gene Expression Regulation, Neoplastic; Green Fluorescent Proteins; Humans; Immunohistochemistry; Lentivirus Infections; Mice; Mice, Inbred BALB C; Mice, Nude; Neovascularization, Pathologic; Niacinamide; Oligonucleotide Array Sequence Analysis; Phenylurea Compounds; Phosphorylation; Protein Serine-Threonine Kinases; Pyridines; Receptor, Transforming Growth Factor-beta Type II; Receptors, Transforming Growth Factor beta; Reverse Transcriptase Polymerase Chain Reaction; RNA, Neoplasm; Signal Transduction; Smad2 Protein; Sorafenib; Stomach Neoplasms; Thrombospondin 1; Transforming Growth Factor beta; Transplantation, Heterologous; Vascular Endothelial Growth Factor A	2009
Hemangiopericytoma and antiangiogenic therapy: clinical benefit of antiangiogenic therapy (sorafenib and sunitinib) in relapsed malignant haemangioperyctoma /solitary fibrous tumour. Investigational new drugs, 2010, Volume: 28, Issue:2 Topics: Aged; Angiogenesis Inhibitors; Benzenesulfonates; Fatal Outcome; Female; Hemangiopericytoma; Humans; Indoles; Middle Aged; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Recurrence; Solitary Fibrous Tumors; Sorafenib; Sunitinib; Tomography, X-Ray Computed; Ultrasonography	2010
Does arterial spin-labeling MR imaging-measured tumor perfusion correlate with renal cell cancer response to antiangiogenic therapy in a mouse model? Radiology, 2009, Volume: 251, Issue:3 Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Image Processing, Computer-Assisted; Kidney Neoplasms; Linear Models; Magnetic Resonance Imaging; Mice; Mice, Nude; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Spin Labels	2009
Tumor endothelial cells join the resistance. Clinical cancer research : an official journal of the American Association for Cancer Research, 2009, Aug-01, Volume: 15, Issue:15 Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Carcinoma, Hepatocellular; Cells, Cultured; Drug Resistance, Neoplasm; Endothelium, Vascular; Humans; Liver Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Pyridines; Ranibizumab; Sorafenib	2009
Human hepatocellular carcinoma tumor-derived endothelial cells manifest increased angiogenesis capability and drug resistance compared with normal endothelial cells. Clinical cancer research : an official journal of the American Association for Cancer Research, 2009, Aug-01, Volume: 15, Issue:15 Topics: Antigens, CD; Antineoplastic Agents; Apoptosis; Benzenesulfonates; Cadherins; Carcinoma, Hepatocellular; Cell Adhesion; Cell Line, Tumor; Cell Movement; Cell Survival; Doxorubicin; Drug Resistance, Neoplasm; Endoglin; Endothelium, Vascular; Fluorouracil; Humans; Liver Neoplasms; Mitogen-Activated Protein Kinase Kinases; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Platelet Endothelial Cell Adhesion Molecule-1; Proto-Oncogene Proteins c-akt; Pyridines; Receptors, Cell Surface; Signal Transduction; Sorafenib; STAT3 Transcription Factor; Vascular Endothelial Growth Factor Receptor-1; Vascular Endothelial Growth Factor Receptor-2; von Willebrand Factor	2009
A computational approach to compare microvessel distributions in tumors following antiangiogenic treatments. Laboratory investigation; a journal of technical methods and pathology, 2009, Volume: 89, Issue:9 Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Benzenesulfonates; Cell Line, Tumor; Computational Biology; Humans; Image Interpretation, Computer-Assisted; Mice; Mice, SCID; Microvessels; Neoplasm Transplantation; Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Xenograft Model Antitumor Assays	2009
Sorafenib attenuates the portal hypertensive syndrome in partial portal vein ligated rats. Journal of hepatology, 2009, Volume: 51, Issue:5 Topics: Angiogenesis Inhibitors; Animals; Benzenesulfonates; Cell Proliferation; Cytokines; Down-Regulation; Hemodynamics; Hypertension, Portal; Ligation; Male; Neovascularization, Pathologic; Niacinamide; Nitric Oxide Synthase Type III; Phenylurea Compounds; Portal Vein; Protein Kinase Inhibitors; Pyridines; Rats; Rats, Sprague-Dawley; RNA, Messenger; Sorafenib; Splanchnic Circulation	2009
Everolimus: in advanced renal cell carcinoma. Drugs, 2009, Oct-22, Volume: 69, Issue:15 Topics: Benzenesulfonates; Carcinoma, Renal Cell; Cell Proliferation; Clinical Trials, Phase III as Topic; Disease-Free Survival; Double-Blind Method; Everolimus; Humans; Immunosuppressive Agents; Indoles; Kidney Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Placebos; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sirolimus; Sorafenib; Sunitinib; Treatment Outcome	2009
AZD6244 enhances the anti-tumor activity of sorafenib in ectopic and orthotopic models of human hepatocellular carcinoma (HCC). Journal of hepatology, 2010, Volume: 52, Issue:1 Topics: Animals; Antineoplastic Agents; Apoptosis; Benzenesulfonates; Benzimidazoles; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; Drug Synergism; Extracellular Signal-Regulated MAP Kinases; Humans; Liver Neoplasms; Male; Mice; Mice, SCID; Mitogen-Activated Protein Kinases; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Pyridines; raf Kinases; Signal Transduction; Sorafenib; Xenograft Model Antitumor Assays	2010
Sorafenib blocks tumour growth, angiogenesis and metastatic potential in preclinical models of osteosarcoma through a mechanism potentially involving the inhibition of ERK1/2, MCL-1 and ezrin pathways. Molecular cancer, 2009, Dec-10, Volume: 8 Topics: Animals; Antineoplastic Agents; Apoptosis; Benzenesulfonates; Cell Division; Cell Line, Tumor; Cytoskeletal Proteins; Down-Regulation; Extracellular Signal-Regulated MAP Kinases; Female; Humans; Male; Matrix Metalloproteinase 2; Matrix Metalloproteinase Inhibitors; Mice; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasm Metastasis; Neovascularization, Pathologic; Niacinamide; Osteosarcoma; Phenylurea Compounds; Proto-Oncogene Proteins c-bcl-2; Pyridines; Sorafenib; Vascular Endothelial Growth Factor A	2009
Evaluation of response in malignant tumors treated with the multitargeted tyrosine kinase inhibitor sorafenib: a multitechnique imaging assessment. AJR. American journal of roentgenology, 2010, Volume: 194, Issue:1 Topics: Adrenal Gland Neoplasms; Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Contrast Media; Female; Humans; Kidney Neoplasms; Liver Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Pheochromocytoma; Protein Kinase Inhibitors; Pyridines; Sensitivity and Specificity; Sorafenib; Tomography, X-Ray Computed; Treatment Outcome; Ultrasonography	2010
Inhibition of tumor angiogenesis by the matrix metalloproteinase-activated anthrax lethal toxin in an orthotopic model of anaplastic thyroid carcinoma. Molecular cancer therapeutics, 2010, Volume: 9, Issue:1 Topics: Animals; Antigens, Bacterial; Bacterial Toxins; Benzenesulfonates; Carcinoma; Cell Line, Tumor; Cell Proliferation; Endocytosis; Humans; Matrix Metalloproteinases; Mice; Mice, Nude; Mitogen-Activated Protein Kinases; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Survival Analysis; Thyroid Neoplasms; Time Factors; Xenograft Model Antitumor Assays	2010
Impact of metronomic UFT/cyclophosphamide chemotherapy and antiangiogenic drug assessed in a new preclinical model of locally advanced orthotopic hepatocellular carcinoma. Neoplasia (New York, N.Y.), 2010, Volume: 12, Issue:3 Topics: Animals; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Hepatocellular; Cell Line, Tumor; Chorionic Gonadotropin, beta Subunit, Human; Cyclophosphamide; Doxorubicin; Female; Humans; Injections, Subcutaneous; Liver Neoplasms, Experimental; Mice; Mice, Nude; Mice, SCID; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Survival Rate; Tegafur; Treatment Outcome; Uracil; Xenograft Model Antitumor Assays	2010
Sorafenib exerts anti-glioma activity in vitro and in vivo. Neuroscience letters, 2010, Jul-12, Volume: 478, Issue:3 Topics: Animals; Antineoplastic Agents; Apoptosis; Autophagy; Benzenesulfonates; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; Dose-Response Relationship, Drug; Female; Glioblastoma; Glioma; Mice; Mice, Nude; Neoplasm Transplantation; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Random Allocation; Sorafenib; Treatment Outcome	2010
Synergistic activity of sorafenib and sulforaphane abolishes pancreatic cancer stem cell characteristics. Cancer research, 2010, Jun-15, Volume: 70, Issue:12 Topics: Aldehyde Dehydrogenase; Aldehyde Dehydrogenase 1 Family; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzenesulfonates; Blotting, Western; Cell Proliferation; Cells, Cultured; Colony-Forming Units Assay; Drug Synergism; Electrophoretic Mobility Shift Assay; Female; Fibroblasts; Humans; Immunoblotting; Immunoenzyme Techniques; Isoenzymes; Isothiocyanates; Luciferases; Mice; Mice, Nude; Neoplastic Stem Cells; Neovascularization, Pathologic; NF-kappa B; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Pyridines; Retinal Dehydrogenase; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Skin; Sorafenib; Spheroids, Cellular; Sulfoxides; Thiocyanates; Xenograft Model Antitumor Assays	2010
Sorafenib's inhibition of prostate cancer growth in transgenic adenocarcinoma mouse prostate mice and its differential effects on endothelial and pericyte growth during tumor angiogenesis. Analytical and quantitative cytology and histology, 2010, Volume: 32, Issue:3 Topics: Adenocarcinoma; Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Benzenesulfonates; Disease Progression; Drug Screening Assays, Antitumor; Endothelium, Vascular; Fluorescent Antibody Technique, Direct; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Neovascularization, Pathologic; Niacinamide; Pericytes; Phenylurea Compounds; Prostatic Intraepithelial Neoplasia; Prostatic Neoplasms; Pyridines; Sorafenib; Treatment Outcome	2010
Sorafenib enhances the in vitro anti-endothelial effects of low dose (metronomic) chemotherapy. Oncology reports, 2010, Volume: 24, Issue:4 Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Drug Administration Schedule; Endothelial Cells; Etoposide; Humans; In Vitro Techniques; Neovascularization, Pathologic; Niacinamide; Paclitaxel; Phenylurea Compounds; Pyridines; Sorafenib; Temozolomide	2010
Monitoring blood-brain barrier status in a rat model of glioma receiving therapy: dual injection of low-molecular-weight and macromolecular MR contrast media. Radiology, 2010, Volume: 257, Issue:2 Topics: Analysis of Variance; Animals; Area Under Curve; Benzenesulfonates; Blood-Brain Barrier; Brain Neoplasms; Contrast Media; Disease Models, Animal; Glioma; Heterocyclic Compounds; Macromolecular Substances; Magnetic Resonance Imaging; Male; Neovascularization, Pathologic; Niacinamide; Organometallic Compounds; Phenylurea Compounds; Pyridines; Random Allocation; Rats; Sorafenib	2010
Combining functional imaging and interstitial pressure measurements to evaluate two anti-angiogenic treatments. Investigational new drugs, 2012, Volume: 30, Issue:1 Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Contrast Media; Drug Administration Schedule; Extracellular Fluid; Female; Fiber Optic Technology; Melanoma, Experimental; Mice; Neovascularization, Pathologic; Niacinamide; Perfusion Imaging; Phenylurea Compounds; Phospholipids; Pressure; Pyridines; Regional Blood Flow; Sorafenib; Sulfur Hexafluoride; Time Factors; Transducers, Pressure; Ultrasonography, Doppler	2012
Inhibition of angiogenic and non-angiogenic targets by sorafenib in renal cell carcinoma (RCC) in a RCC xenograft model. British journal of cancer, 2011, Mar-15, Volume: 104, Issue:6 Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Dose-Response Relationship, Drug; Down-Regulation; Humans; Kidney Neoplasms; Male; Mice; Mice, SCID; Molecular Targeted Therapy; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Tumor Cells, Cultured; Xenograft Model Antitumor Assays	2011
Everolimus augments the effects of sorafenib in a syngeneic orthotopic model of hepatocellular carcinoma. Molecular cancer therapeutics, 2011, Volume: 10, Issue:6 Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carrier Proteins; Cell Proliferation; Drug Synergism; Everolimus; Extracellular Signal-Regulated MAP Kinases; Intracellular Signaling Peptides and Proteins; Liver Neoplasms, Experimental; Male; Mitogen-Activated Protein Kinase 3; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Phosphoproteins; Pyridines; Random Allocation; Rats; Sirolimus; Sorafenib; Tumor Burden; Vascular Endothelial Growth Factor A	2011
Synergistic cytotoxicity, inhibition of signal transduction pathways and pharmacogenetics of sorafenib and gemcitabine in human NSCLC cell lines. Lung cancer (Amsterdam, Netherlands), 2011, Volume: 74, Issue:2 Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzenesulfonates; Carcinoma, Non-Small-Cell Lung; Cell Growth Processes; Cell Line, Tumor; Deoxycytidine; Drug Synergism; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; MAP Kinase Signaling System; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Phosphatidylethanolamine Binding Protein; Phosphorylation; Proto-Oncogene Proteins c-kit; Pyridines; raf Kinases; Receptors, Vascular Endothelial Growth Factor; Sorafenib	2011
Sorafenib enhances the antitumor effects of chemoradiation treatment by downregulating ERCC-1 and XRCC-1 DNA repair proteins. Molecular cancer therapeutics, 2011, Volume: 10, Issue:7 Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cells, Cultured; DNA-Binding Proteins; Dose-Response Relationship, Drug; Down-Regulation; Endonucleases; Endothelial Cells; Gene Expression Regulation, Neoplastic; Humans; Mice; Mice, SCID; Neoplasms; Neoplastic Stem Cells; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Pyridines; Radiation Tolerance; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Tumor Burden; X-ray Repair Cross Complementing Protein 1; Xenograft Model Antitumor Assays	2011
An investigation of the effect of sorafenib on tumour growth and recurrence after liver cancer resection in nude mice independent of phosphorylated extracellular signal-regulated kinase levels. Expert opinion on investigational drugs, 2011, Volume: 20, Issue:8 Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Biomarkers, Tumor; Cell Growth Processes; Cell Line, Tumor; Chemotherapy, Adjuvant; Extracellular Signal-Regulated MAP Kinases; Hep G2 Cells; Humans; Liver Neoplasms; Lung Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Phosphorylation; Protein Kinase Inhibitors; Pyridines; Sorafenib; Xenograft Model Antitumor Assays	2011
Sorafenib enhances pemetrexed cytotoxicity through an autophagy-dependent mechanism in cancer cells. Autophagy, 2011, Volume: 7, Issue:10 Topics: Animals; Antineoplastic Agents; Autophagy; Benzenesulfonates; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Synergism; Gene Expression Regulation, Neoplastic; Glutamates; Guanine; Humans; Liver Neoplasms; Mice; Neoplasm Transplantation; Neoplasms; Neovascularization, Pathologic; Niacinamide; Pemetrexed; Phenylurea Compounds; Phosphorylation; Protein Kinase Inhibitors; Pyridines; Sorafenib	2011
Comparing the efficacy of sunitinib with sorafenib in xenograft models of human hepatocellular carcinoma: mechanistic explanation. Current cancer drug targets, 2011, Volume: 11, Issue:8 Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Benzenesulfonates; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Humans; Indoles; Liver Neoplasms; Male; MAP Kinase Signaling System; Mice; Mice, SCID; Neoplasm Proteins; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Random Allocation; Sorafenib; Sunitinib; Xenograft Model Antitumor Assays	2011
Differential modulatory effects of GSK-3β and HDM2 on sorafenib-induced AIF nuclear translocation (programmed necrosis) in melanoma. Molecular cancer, 2011, Sep-19, Volume: 10 Topics: Animals; Antineoplastic Agents; Apoptosis; Apoptosis Inducing Factor; Apoptosis Regulatory Proteins; Benzenesulfonates; Cell Line, Tumor; Cell Nucleus; Cell Survival; Cyclin-Dependent Kinase Inhibitor p21; Drug Synergism; Female; Gene Expression; Gene Knockdown Techniques; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Humans; Indoles; Melanoma; Mice; Mice, Nude; Mitochondria; Necrosis; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Protein Transport; Proto-Oncogene Proteins c-mdm2; Pyridines; RNA Interference; Sorafenib; Spiro Compounds; Tumor Burden; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays	2011
AFP measurement in monitoring treatment response of advanced hepatocellular carcinoma to sorafenib: case report and review of the literature. Onkologie, 2011, Volume: 34, Issue:10 Topics: alpha-Fetoproteins; Antineoplastic Agents; Benzenesulfonates; Biomarkers, Tumor; Carcinoma, Hepatocellular; Disease Progression; Dose-Response Relationship, Drug; Humans; Image Processing, Computer-Assisted; Liver; Liver Neoplasms; Male; Middle Aged; Multidetector Computed Tomography; Neoplasm Invasiveness; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Pyridines; Retrospective Studies; Sorafenib; Treatment Outcome	2011
Sorafenib inhibits neuroblastoma cell proliferation and signaling, blocks angiogenesis, and impairs tumor growth. Pediatric blood & cancer, 2012, Volume: 59, Issue:4 Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Benzenesulfonates; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Female; MAP Kinase Signaling System; Mice; Mice, Nude; Neoplasm Transplantation; Neovascularization, Pathologic; Neuroblastoma; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib	2012
Treatment effects of the multikinase inhibitor sorafenib on hepatoblastoma cell lines and xenografts in NMRI-Foxn1 nu mice. Liver international : official journal of the International Association for the Study of the Liver, 2012, Volume: 32, Issue:4 Topics: alpha-Fetoproteins; Animals; Antineoplastic Agents; Apoptosis; Benzenesulfonates; Blotting, Western; Caspase 3; Cell Line, Tumor; Cell Survival; Extracellular Signal-Regulated MAP Kinases; Fluorescent Antibody Technique, Indirect; Forkhead Transcription Factors; Hepatoblastoma; In Situ Nick-End Labeling; Mice; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib; Tetrazolium Salts; Thiazoles; Transplantation, Heterologous; Transplants	2012
Combination of Temsirolimus and tyrosine kinase inhibitors in renal carcinoma and endothelial cell lines. Journal of cancer research and clinical oncology, 2012, Volume: 138, Issue:6 Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Drug Therapy, Combination; Human Umbilical Vein Endothelial Cells; Humans; Indoles; Kidney Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Sirolimus; Sorafenib; Sunitinib	2012
RAIN-Droplet: a novel 3D in vitro angiogenesis model. Laboratory investigation; a journal of technical methods and pathology, 2012, Volume: 92, Issue:7 Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Cells, Cultured; Dose-Response Relationship, Drug; Endothelial Cells; Humans; Imaging, Three-Dimensional; Microscopy, Confocal; Microscopy, Electron, Transmission; Microvessels; Models, Biological; Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Spheroids, Cellular	2012
Differential drug class-specific metastatic effects following treatment with a panel of angiogenesis inhibitors. The Journal of pathology, 2012, Volume: 227, Issue:4 Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antineoplastic Agents; Benzamides; Benzenesulfonates; Cell Line, Tumor; Disease Models, Animal; Dose-Response Relationship, Drug; Enzyme Inhibitors; Female; Imatinib Mesylate; In Vitro Techniques; Indoles; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Nude; Neoplasm Metastasis; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Piperazines; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A	2012
Erlotinib and sorafenib in an orthotopic rat model of hepatocellular carcinoma. Journal of hepatology, 2012, Volume: 57, Issue:3 Topics: Animals; Apoptosis; Benzenesulfonates; Carcinoma, Hepatocellular; Cell Movement; Cell Survival; Drug Therapy, Combination; Endothelial Cells; ErbB Receptors; Erlotinib Hydrochloride; Hep G2 Cells; Humans; Liver Neoplasms; Neoplasm Transplantation; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Quinazolines; Rats; RNA, Messenger; Sorafenib; Vascular Endothelial Growth Factor A	2012
Contrast-enhanced ultrasonography for evaluating antiangiogenic treatment in hepatocellular carcinoma. A long way from research to clinical practice. Medical ultrasonography, 2012, Volume: 14, Issue:2 Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Ultrasonography	2012
The monoclonal antibody CH12 enhances the sorafenib-mediated growth inhibition of hepatocellular carcinoma xenografts expressing epidermal growth factor receptor variant III. Neoplasia (New York, N.Y.), 2012, Volume: 14, Issue:6 Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; Apoptosis; Benzenesulfonates; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; MAP Kinase Signaling System; Mice; Mice, Nude; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyridines; Sorafenib; STAT3 Transcription Factor; Xenograft Model Antitumor Assays	2012
Molecular mechanisms of sorafenib action in liver cancer cells. Cell cycle (Georgetown, Tex.), 2012, Aug-01, Volume: 11, Issue:15 Topics: Apoptosis; Benzenesulfonates; Biological Transport; Carcinoma, Hepatocellular; Cell Adhesion; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; DNA Repair; DNA Replication; Gene Expression Profiling; Humans; Liver Neoplasms; Mitogen-Activated Protein Kinases; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Protein Biosynthesis; Protein Kinase Inhibitors; Pyridines; Signal Transduction; Sorafenib; Transcription, Genetic	2012
Targeting angiogenesis in metastatic breast cancer. The oncologist, 2012, Volume: 17, Issue:8 Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Capecitabine; Clinical Trials, Phase III as Topic; Deoxycytidine; Disease-Free Survival; Everolimus; Female; Fluorouracil; Humans; Indoles; Neoplasm Metastasis; Neovascularization, Pathologic; Niacinamide; Paclitaxel; Phenylurea Compounds; Pyrroles; Sirolimus; Sorafenib; Sunitinib; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A	2012
Novel antiangiogenic therapies against advanced hepatocellular carcinoma (HCC). Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2012, Volume: 14, Issue:8 Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Carcinoma, Hepatocellular; Clinical Trials, Phase III as Topic; Humans; Liver Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Sorafenib	2012
Monitoring anti-angiogenic therapy in colorectal cancer murine model using dynamic contrast-enhanced MRI: comparing pixel-by-pixel with region of interest analysis. Technology in cancer research & treatment, 2013, Volume: 12, Issue:1 Topics: Angiogenesis Inhibitors; Animals; Colorectal Neoplasms; Contrast Media; Disease Models, Animal; Humans; Image Processing, Computer-Assisted; Magnetic Resonance Imaging; Mice; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Transplantation, Heterologous	2013
Sorafenib inhibits hypoxia-inducible factor-1α synthesis: implications for antiangiogenic activity in hepatocellular carcinoma. Clinical cancer research : an official journal of the American Association for Cancer Research, 2012, Oct-15, Volume: 18, Issue:20 Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Gene Expression Regulation, Neoplastic; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Liver Neoplasms; Mice; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Phosphorylation; Sorafenib; Transplantation, Heterologous; Vascular Endothelial Growth Factor A	2012
Sorafenib inhibits growth, migration, and angiogenic potential of ectopic endometrial mesenchymal stem cells derived from patients with endometriosis. Fertility and sterility, 2012, Volume: 98, Issue:6 Topics: Adult; Angiogenesis Inhibitors; Benzenesulfonates; Cell Movement; Cell Proliferation; Cells, Cultured; Endometriosis; Endometrium; Female; Humans; Mesenchymal Stem Cells; Middle Aged; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib; Treatment Outcome; Young Adult	2012
The placental growth factor as a target against hepatocellular carcinoma in a diethylnitrosamine-induced mouse model. Journal of hepatology, 2013, Volume: 58, Issue:2 Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; Carcinoma, Hepatocellular; Diethylnitrosamine; Disease Models, Animal; Drug Therapy, Combination; Liver Neoplasms; Mice; Mice, Knockout; Mice, Transgenic; Neoplasm Metastasis; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Placenta Growth Factor; Pregnancy Proteins; Sorafenib; Treatment Outcome	2013
Sorafenib suppresses the rapid progress of hepatocellular carcinoma after insufficient radiofrequency ablation therapy: an experiment in vivo. Acta radiologica (Stockholm, Sweden : 1987), 2013, Mar-01, Volume: 54, Issue:2 Topics: Animals; Antineoplastic Agents; Catheter Ablation; Combined Modality Therapy; Disease Progression; Hypoxia-Inducible Factor 1, alpha Subunit; Immunohistochemistry; Liver Neoplasms, Experimental; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Real-Time Polymerase Chain Reaction; Sorafenib; Vascular Endothelial Growth Factor A	2013
Effect of sorafenib combined with cytostatic agents on hepatoblastoma cell lines and xenografts. British journal of cancer, 2013, Feb-05, Volume: 108, Issue:2 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Survival; Cisplatin; Cytostatic Agents; DNA Adducts; Enzyme Activation; Female; Hepatoblastoma; Humans; Liver Neoplasms; Mice; Mice, Nude; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Sorafenib; Xenograft Model Antitumor Assays	2013
How to improve treatment outcomes for hepatocellular carcinoma of intermediate and advanced stage. Digestive diseases (Basel, Switzerland), 2012, Volume: 30, Issue:6 Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Humans; Liver Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Sorafenib; Yttrium Radioisotopes	2012
PG545, a heparan sulfate mimetic, reduces heparanase expression in vivo, blocks spontaneous metastases and enhances overall survival in the 4T1 breast carcinoma model. PloS one, 2012, Volume: 7, Issue:12 Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cells, Cultured; Disease Progression; Enzyme-Linked Immunosorbent Assay; Female; Glucuronidase; Human Umbilical Vein Endothelial Cells; Humans; Immunoenzyme Techniques; Lung Neoplasms; Mammary Neoplasms, Experimental; Mice; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Saponins; Sorafenib	2012
Sorafenib inhibits tumor growth and improves survival in a transgenic mouse model of pancreatic islet cell tumors. TheScientificWorldJournal, 2012, Volume: 2012 Topics: Adenoma, Islet Cell; Animals; Antigens, Polyomavirus Transforming; Apoptosis; Disease Progression; Female; Insulin; Islets of Langerhans; Kaplan-Meier Estimate; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Neovascularization, Pathologic; Neuroendocrine Tumors; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Promoter Regions, Genetic; Protein Kinase Inhibitors; Rats; Sorafenib; Time Factors; Treatment Outcome; Tumor Burden	2012
Expression of angiogenesis-related gene profiles and development of resistance to tyrosine-kinase inhibitor in advanced renal cell carcinoma: characterization of sorafenib-resistant cells derived from a cutaneous metastasis. International journal of urology : official journal of the Japanese Urological Association, 2013, Volume: 20, Issue:9 Topics: Aneuploidy; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Kidney Neoplasms; Male; Middle Aged; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Primary Cell Culture; Protein Kinase Inhibitors; Skin Neoplasms; Sorafenib; Transcriptome; Tumor Cells, Cultured	2013
Mutant V599EB-Raf regulates growth and vascular development of malignant melanoma tumors. Cancer research, 2005, Mar-15, Volume: 65, Issue:6 Topics: Animals; Apoptosis; Benzenesulfonates; Cell Growth Processes; Cell Line, Tumor; Humans; MAP Kinase Signaling System; Melanoma; Mice; Mutation; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins B-raf; Pyridines; RNA, Small Interfering; Sorafenib; Vascular Endothelial Growth Factor A	2005
Inhibition of tumor endothelial ERK activation, angiogenesis, and tumor growth by sorafenib (BAY43-9006). The American journal of pathology, 2006, Volume: 169, Issue:5 Topics: Animals; Antineoplastic Agents; Apoptosis; Benzenesulfonates; Carcinoma, Renal Cell; Cell Proliferation; Collagen; Drug Combinations; Endothelial Cells; Enzyme Activation; Extracellular Signal-Regulated MAP Kinases; Fibroblast Growth Factor 2; Humans; Kidney Neoplasms; Laminin; Melanoma; Mice; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Phosphorylation; Proteoglycans; Proto-Oncogene Proteins c-akt; Pyridines; Sorafenib	2006
Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer research, 2006, Dec-15, Volume: 66, Issue:24 Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Cell Cycle; Cell Death; Cell Line, Tumor; Cell Survival; Extracellular Signal-Regulated MAP Kinases; Humans; Liver Neoplasms; MAP Kinase Kinase Kinases; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Pyridines; raf Kinases; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Transplantation, Heterologous	2006
Sunitinib malate and sorafenib may be beneficial at the treatment of advanced bladder cancer due to their anti-angiogenic effects. Medical hypotheses, 2007, Volume: 69, Issue:4 Topics: Angiogenesis Inhibitors; Benzenesulfonates; Humans; Indoles; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Pyrroles; Sorafenib; Sunitinib; Urinary Bladder Neoplasms	2007
Clinical factors associated with outcome in patients with metastatic clear-cell renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy. Cancer, 2007, Aug-01, Volume: 110, Issue:3 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Female; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Prognosis; Prospective Studies; Pyridines; Pyrroles; Randomized Controlled Trials as Topic; Sorafenib; Sunitinib; Survival Rate; Vascular Endothelial Growth Factor A	2007
Combination therapy targeting the tumor microenvironment is effective in a model of human ocular melanoma. Journal of translational medicine, 2007, Jul-18, Volume: 5 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Cell Movement; Cell Proliferation; Disease Models, Animal; Endothelial Cells; Eye Neoplasms; Humans; In Vitro Techniques; Lenalidomide; Melanoma; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Pyridines; Rats; Rats, Sprague-Dawley; Sorafenib; Thalidomide; Xenograft Model Antitumor Assays	2007
Combination of radiofrequency ablation with antiangiogenic therapy for tumor ablation efficacy: study in mice. Radiology, 2007, Volume: 244, Issue:2 Topics: Analysis of Variance; Animals; Benzenesulfonates; Carcinoma, Renal Cell; Catheter Ablation; Combined Modality Therapy; Kidney Neoplasms; Mice; Mice, Nude; Neoplasm Transplantation; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Prospective Studies; Protein Kinase Inhibitors; Pyridines; Sorafenib; Statistics, Nonparametric	2007